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Abstract  
Undifferentiated cancer stem cells (CSCs) with their unique potential of self-renewal 
and multi-lineage differentiation fuel tumour growth and relapse. Efficacy of glioma 
therapy can be considerably improved if the target is focused towards successful 
identification and elimination of CSCs. The aim of this research lies in defining specific 
and selective marker(s) to isolate glioma stem cells, to explore the differentiation state 
of brain tumour cells and to determine the protein profile changes that assist tumour 
cells to sustain stem cell-like characteristics. The three stem cell-related protein 
(CD133, Oct4-A and BMP3) expressions were investigated in control, hypoxic and 
serum-deprived U87-MG cells in order to shed light on the influence the micro-
environment has in generating stem cells. Hypoxia offered a rapid state of 
undifferentiation as compared to serum deprivation by expressing a basal level of 
CD133 protein, a designated stem cell marker. Subsequent measurements of 
chemosensitivity and cell cycle analysis under undifferentiation conditions added to 
the cytotoxic potential of Taxol and showed an enhanced sensitivity of serum-deprived 
cells towards chemotherapeutic drugs. 
Moreover, proteomic analysis produced a wide dataset, depicting the changes that 
occur at the proteomic level in the differentiated and undifferentiated U87-MG cells. 
With ingenuity pathway analysis (IPA), human protein research database (HPRD) and 
the literature review, several proteins were proposed to be tested as potential 
biomarkers. They included Uracil DNA glycosylase (UDG), Phosphoglycerate kinase 1 
(PGK1), Heterogeneous nuclear riboprotein K (HNRNPK) and moesin that can be used 
as differentiated markers for glioma cells. Vimentin, Eukaryotic translation initiation 
factor 4e (EIF4e), Casein kinase II alpha 1 (CSNK2A1) should be further investigated to 
study their precise role in gliomagenesis. Laminin binding protein associated with 
Integrin α6β1 and BMP2 should also be explored as a potential biomarker for isolation 
of glioma stem cells. 
This novel study envelops diverse aspects related to CSCs such as biomarkers, stem cell 
niche, chemoresistance, cell cycle and proteomics and also suggests the existence of 
two sub-types of CSCs within glioma population. It can be concluded that the finding 
thus obtained may be a step in the right direction in helping treat brain tumours. 
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1.1  Glioma  
Gliomas or brain tumours originate from glial cells of the brain. Glial cells unlike 
neurones have a property of cell division, a loss of controlled cell proliferation is found 
to result in a brain tumour. The abnormality of cells combined with the efficiency of 
their growth rate categorizes brain tumours into grades 1 to 4. Grades 1 and 2 indicate 
a low grade of glioma and grades 3 and 4 represent a higher stage of brain tumour 
(Shinohara et al., 2008). Glioma can be both benign and malignant, where 
approximately more than 50 % of them show highly malignant and aggressive 
behaviour (Weil et al., 2006). A low grade glioma is less aggressive and grows slowly, 
whereas, high grade brain tumours are highly vascular with a tendency to infiltrate in 
the surrounding tissues. Most of the high grade tumours are found to reoccur even 
after surgical resection (Nobuyoshi et al., 2006). Brain tumours are reported to be 
highly heterogeneous expressing phenotypes of cells belonging to more than one 
neuronal lineage which could be either differentiated or undifferentiated (Pomeroy et 
al., 2002). There are several types of brain tumours such as astrocytomas that grow 
throughout the brain, ependymomas develops in the lining of the ventricles and 
oligodendrogliomas develop in the cerebrum (Kondziolka and Bilbao 1988). The 
progression from low to high grade glioma involves a series of accumulated genetic 
mutations inactivating specific tumour suppressor genes namely TP53, p16, RB or PTEN 
or are found to activate oncogenes MDM2, CDK4 and CDK6 (Kleiheus and Cavenee, 
2000; Maher et al., 2001). The most common treatment employed to treat glioma 
includes surgical resection of the tumour, stereotactic radio surgery, radiation and 
chemotherapy with the application of approved drugs (Weil et al., 2006). However, 
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chemotherapeutic drug strategies together with surgery and radiation therapies have 
till now been unable to completely cure cancer, tumour metastasis and relapse. 
1.2 Cancer Stem Cells (CSCs) 
The human brain accommodates a group of self-renewing stem cells throughout their 
life (Gage et al., 2000). This small population of stem cells are predominantly 
maintained in an undifferentiated state, accompanied by a potential of self-renewal 
and multi-lineage differentiation. Normal stem cells (NSCs) assist in the repair and 
regeneration of damaged areas of the CNS. However, mutations (Fig. 1.1) and 
epigenetic alterations can coerce them to be transformed into cancer stem cells (CSCs) 
giving them the indefinite potential to differentiate into a tumorigenic lineage        
(Reya et al., 2001). 
 
 
 
    
 
Figure 1.1: Cancer stem cell hypotheses. Transformation of a stem cell (SC) into a CSC on 
account of multiple mutations. (Adapted from http://www.allthingsstemcell.com/wp-
content/uploads/ 2009/09/p53_cancer_cell_formation-copy2.png) 
It has been observed that most of the tumours arise from the zone where stem cells 
reside, specifically the sub-ventricular zone in proximity to the walls of the ventricular 
system (Globus et al., 1944). The majority of the therapies focus on eliminating the 
tumour mass, while ignoring the chemo- and radio-resistance capability of CSCs, 
providing them the opportunity to repopulate (Fig 1.2).  
   Multiple mutations  
   Stem Cell  
Multiple Mutations 
 Cancer Stem Cell  
  SC  CSC 
 Self-Renewal  
 Epigenetic alterations 
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Figure 1.2: Cancer therapies. Illustration of efficiency cancer therapies when targeting at 
tumour mass and cancer stem cells respectively. (Modified from 
http://drugdiscoveryopinion.com /images/cancer_stem_cells.jpg) 
 
CSCs are known to elicit a genetically defective response towards the epigenetic 
stimuli leading to cancer progression by compromising tumour suppressor genes 
(Rajaraman et al., 2006). A genetic alteration in the pathway resulting in the loss of the 
tumour suppressor gene Ink4a-Arf can transform the astrocytes to a tumour 
progenitor cell (Bachoo et al., 2002). The signalling pathways such as Bmi 1 and Wnt 
have been proven to have similar effects on NSCs and CSCs self-renewal. This indicates 
that there exists a common molecular pathway regulating both populations. The 
deregulation of signalling pathways culminate in the actual loss of stemness control in 
NSCs and this needs to be further explored (Fargeas et al., 2003).  
 
     Tumour mass  
   Tumour regression  
 Tumour relapse  
Cancer stem cell 
specific therapy 
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Stem cells at present have therefore become one of the crucial targets to study the 
diverse aspects of cancer intensification and maintenance. This small group of cells 
have been identified by means of a marker expression showing an extensive 
proliferation to form tumours (Singh et al., 2003). Common markers for NSCs and CSCs 
include prominin-1 (CD133; CSC marker), nestin (Nes; NSC marker), mushashi          
(Msi; NSC marker, cell fate determinant), octamer-binding transcription factor 4    
(Oct4; undifferentiated stem cell marker) and bone morphogenetic proteins (BMPs; 
stem cell fate determinant, differentiation) (Bao et al., 2006). Elevated levels of nestin 
have been considered as a prognostic marker for glioma malignancy, whereas, a 
relatively weak mushashi expression with loss of its regulatory function has reduced its 
clinical significance in treating glioma (Strojnik et al., 2007). The existence of stem cells 
in both normal and malignant brain tissue has been successfully identified by the 
presence of CD133, a designated stem cell surface marker (Singh et al., 2003). 
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1.3  Stem cell markers 
1.3.1 CD133 
Various human tissue samples express CD133; however, the glycosylated epitope 
AC133 of the CD133 antigen is found only on stem cells and is down regulated after 
the onset of differentiation (Kemper et al., 2010). CD133 is a 20kDa, 5-transmembrane 
domain surface glycoprotein (Fig 1.3) with an unknown function. Prominin-1/CD133 
has been reported to be localised in the protrusions of the apical membrane in the 
neuroepithelial cells where it plays an important role in the maintenance of           
apical-basal polarity (Kosodo et al., 2004). 
 
 
Figure 1.3: CD133, transmembrane glycoprotein. Localisation of CD133 on the cell surface. 
(Modified from http://www.biotec.tu-dresden.de/research/corbeil/) 
 
 
CD133 
Protein 
 
 
PRO 
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The initial identification and characterisation of CSCs from glioma tissue was based on 
the sorting of CD133+ cells within a dissociated tumour cell mass (Singh et al., 2003). In 
glioblastoma, CD133+ cells maintained a dormant state, however, when required they 
could enter the proliferative cell cycle phase to produce a highly progressive progeny         
(Lui and Zhang, 2009). As a requisite for a stem cell, CD133+ cells express a                  
sex-determining region called the Y-box-2 (SOX2; regulates self-renewal and 
undifferentiated state of stem cells) and extracellular matrix receptor III genes (CD44; 
stem adhesion and invasion), required for self-renewal and could differentiate into 
CD133- cell progeny, representing a major portion of the glioblastoma (Liu et al., 2009). 
The percentage of CD133+ cells were found to increase following radiation therapy, 
further contributing to radio-resistance by activation of deoxyribonucleic acid (DNA) 
damage checkpoints (Bao et al., 2006). These cancer causing cells in comparison to 
NSCs were found to be resistant to the tumour necrosis factor (TNF) related apoptosis 
ligand (TRAIL/Apo2L) (Capper et al., 2009). The expression of the CD133 protein and 
the drug resistant genes such as the multi-drug resistant gene product 1               
(MDR1; neurospheres formation, stem cell self-renewal and drug resistance) and B-cell 
lymphoma 2 (Bcl-2; anti-apoptotic protein, drug resistance) were evaluated in 
glioblastoma and normal human cell lines (Shervington and Lu, 2008). The expression 
profile of CD133+ cells was higher in glioma cells compared to the normal astrocytes, 
however, both normal and glioma CD133+ cells showed an increased drug resistance 
capability as compared to CD133- cells (Shervington and Lu, 2008). These data further 
advocates a link between chemotherapy and multi-drug resistance in brain tumours. In 
addition, histological analysis and the quantitative expression of CD133 antigen within 
various glioma cell populations draw a correlation, where a high expression of CD133 
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protein was associated with a reduced probability of patient survival (Zeppernick et al., 
2008). An elevated CD133 protein level was considered to be a risk factor for tumour 
proliferation and progression of malignancy. These results provide sufficient evidence 
proving that CD133+ cells are CSCs, and thus increase the feasibility to utilize it as a 
potential therapeutic target in the treatment of glioma (Shervington and Lu, 2008). 
The concept of CD133+ as CSCs, however, does not address tumour relapse even after 
the administration of potent therapies (Bao et al., 2006). The methods used for the 
purification and sorting of CD133+ cells from CD133- cells have been re-examined in 
fresh human gliomas and gliomasphere cultures. The data showed that there are no 
significant differences found in the expression of stemness genes or the long-term   
self-renewal capacities of CD133+ and CD133- cells (Clement et al., 2009). In vivo 
experiments showed that CD133- cells obtained from glioma patients when implanted 
in nude rats, yielded tumours and only a few of the resultant tumours were found to 
comprise of CD133+ cells (Wang et al., 2008). CD133 protein was also detected on the 
neural progenitor cells isolated from the post-mortem human cortex and its expression 
was noticeably reduced in high-passage lineage-restricted cultures                       
(Schwartz et al., 2003). Such variation in the expression of CD133 protein poses a 
question mark on its stemness status and raises a doubt as to whether CD133+ cells are 
tumour-initiating stem cells or progenitors that have acquired stem cell functions. 
A stem cell is required to self-renew and differentiate into various progenitors, and 
simultaneously maintain itself in an undifferentiated state. CD133+ cells maintain only 
a subset of primary glioblastoma, whereas the origination of other tumours is 
inherited from the CD133- cells. The differential growth characteristic of CD133+ and  
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CD133- cells reflects two dissimilar subtypes of glioblastoma; however, they specify an 
equal potency to develop into brain tumours (Beier et al., 2007). In addition, the cell 
cycle profile of CD133 cells shows that CD133- cells reside in the G1/G0 phase while the 
CD133+ cells are mainly inhabited in the S/G2 or S/M phase (Sun et al., 2009). This 
increases the likelihood of CD133- cells to generate tumours even while residing in a 
quiescent state. The detection and isolation of substantial quantities of CD133+ cells 
still remains uncertain due to the non-specific binding of glioma cells to micro-beads 
(Clement et al., 2009).  
1.3.2 Oct4-A 
Oct4 (Pou5f1), a POU-homeodomain transcription factor, plays a crucial role in           
self-renewal, pluripotency (Fig. 1.4), and lineage commitment of the stem cells. Being 
an essential factor for differentiation during the early embryonic stages, Oct4 gene is 
silenced in somatic tissues (Lengner et al., 2007).  
An abnormal Oct4 expression in an adult tissue may consequently indicate a 
discrepancy in the process of cell differentiation. In addition, the expression of Oct4 
gene has been reported to enhance tumorigenicity in a dose-dependent manner 
(Gidekel et al., 2003). The Oct4 gene on chromosome 6, encodes for two different 
alternatively spliced variants Oct4-A and Oct4-B, respectively. Oct4-A is composed of 
360 amino acids and is sited within the nucleus, whereas, Oct4-B comprises of 265 
amino acids and is predominant in the cytoplasm (Wang and Dai, 2010). Although both 
isoforms have a similar 225 C-terminal amino acid sequence, they differ with respect 
to the N-terminal (Lee et al., 2006). This structural disparity endows them with 
different functional properties. Comparative studies have shown that Oct4-A is 
responsible for pluripotency and transcription of various genes, whereas, Oct4-B does 
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not sustain stem cell properties. The expression of Oct4 gene has been linked to 
several aspects of self-renewal in the embryonic and adult stem cells                     
(Nichols et al., 1998; Boyer et al., 2005). However, its occurrence in the somatic tissue 
is questionable due to the presence of Oct4 pseudo genes. The resemblance of the 
pseudo genes was found to be higher towards the Oct4-A compared to Oct4-B, 
resulting in multiple probabilities depicting false positive results. Adult stem cells 
expressing Oct4 gene can be used to define the initiation point of cancer (Atlasi et al., 
2008). 
 
 
 
Figure 1.4: Pluripotency pathways. Pathways contributing to stem cell pluripotency via Oct4. 
(Adapted from http://njms.umdnj.edu/gsbs/stemcell/scofthemonth/esc/2.jpg) 
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Figure 1.5: Gene Regulatory Network of Transcription Factor family Oct4 in human.  Ellipses represent the transcription factors belonging to the POU family. 
Boxes symbolize the genes. In case of Oct4 /POU5F1 genes regulated include fibroblast growth factor-4 (FGF4), Small proline-rich protein 3 (SPRP3), Growth 
arrest and DNA-damage-inducible protein GADD45 alpha (GADD45A), Tyrosinase-related protein 1 (TRP1) and Vasoactive intestinal peptide (VIP).  Hexagons 
correspond to the number of clustered genes. Red lines indicate that the protein-DNA binding is known.  The 11 regulated clustered genes are: Friend 
leukaemia virus integration 1 (FLI1), Sex determining region Y { SRY } - box 9 (SOX9), Chorionic gonadotropin beta (CGB), Collagen type II alpha 1 (COL2A1), 
Dopamine Decarboxylase (DDC), Forkhead box D3 (FOXD3), High-mobility group protein B1 (HMGB1), High-mobility group protein B2 (HMGB2), Interferon 
epsilon 1 (IFNE1), Alpha platelet-derived growth factor receptor (PDGFRA) and Undifferentiated embryonic cell transcription factor 1 (UTF1). (Adapted from 
http://rulai.cshl.edu/TRED/GRN/Oct.htm).
Oct4 
28 
 
1.3.3 BMP-2  
While Oct4-A is associated with stem cell pluripotency, the bone morphogenetic 
proteins (BMPs) produce a promotion or inhibition of the astrocytic lineage         
(Nakano et al., 2008). The gene expressions of the two BMP isoforms, BMP2 and BMP4 
have been observed extensively in glioma, performing diverse functions. BMP4 protein 
has been found to promote astro-glial differentiation by reducing symmetric divisions, 
thereby depleting the CSCs population (Piccrillo and Vescovi, 2006). This inhibition is 
achieved by the FRAP-STAT pathway involving FKBP12/rapamycin associated protein 
(FRAP), the Signal Transducers and Activators of Transcription (STAT) proteins (Rajan et 
al., 2003). In vivo data illustrated that the delivery of BMP4 down regulated CD133 
expression by 50 % and BMP4 pre-treated CD133+ cells formed defined, non-invasive 
tumours in immune-deficient mice compared to untreated cells which developed large 
tumours (Piccrillo et al., 2006). 
On the other hand, BMP2 regulates cell differentiation and proliferation                     
(Rios et al., 2004). BMP2 is down regulated in differentiated somatic cells, and 
contributes to stem cell survival and self-renewal. Astrocytic tumours express a high 
level of BMP2 protein in comparison to the normal human astrocytes (NHA). Inhibition 
of this protein using small interfering ribonucleic acids (RNAs) {siRNA} reduced glioma 
cell proliferation and migration (Lu et al., 2006). Furthermore, a high expression of 
BMP2 in different grades of glioma has been shown to increase its clinical relevance 
and makes it a selective marker for the prognosis of glioma (Liu et al., 2009). The level 
BMP2 protein within the glioma cell population would help predict the extent of 
undifferentiated state of brain tumour cells attained on induction of micro-
environmental changes.  
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1.4 Undifferentiation  
Undifferentiation is one of the key features of stem cells. Changes in the properties of 
the undifferentiated brain tumour cells were studied by induction of                         
micro-environmental changes in order to obtain an insight into the deregulated 
pathways in glioma. A differentiated U87-MG cell line was subjected to serum 
deprivation and hypoxia in order to promote their undifferentiation and to focus on 
the stem cell-like properties. The expression of CD133, Oct4-A was thus evaluated to 
confirm the presence of stem-like cells or its progenitors. 
 
 
Figure 1.6: Glioma cell undifferentiation. Enrichment of CSCs on induction of serum 
deprivation and hypoxia. (Modified from http://www.mmf.umn.edu/initiatives/wh/2009/ 
Spring/ funding.cfm) 
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1.4.1 i) Serum deprivation 
Cancer cells attain immortality by ignoring growth inhibitory signals and proliferating in 
the absence of stimulatory growth signals. They propagate in lack of serum as their cell 
cycle phase is independent of the interactions between growth factors and surface 
located receptors (Karp, 2009). Breast cancer cells when exposed to serum deprivation 
indicated an increased tumour cell invasion mediated by Phosphoinositide 3-kinase 
(Reshkin et al., 2000). Evaluation of cells under serum-deprived conditions was 
undertaken in order to study the response of human glioblastoma. A gradual increase 
in the concentration of serum-free neural stem cell culture medium with and without 
vincristine has been reported to be a simple and effective method of isolating CSCs 
from U87-MG cells (Yu et al., 2008). In addition, an up-regulation of CD133 was 
observed as a result of decreasing serum supplement levels in GOS-3 cells (Shervington 
and Lu, 2008). As proposed by stem cell sciences (UK), cancer cells when subjected to 
serum free media (RHB-A) undergo differentiation, whereas the addition of 
supplements such as human epidermal growth factor (hEGF) and basic fibroblast 
growth factor (bFGF) drives the cells towards undifferentiation. The growth factor EGF 
induces motility owing to chemotaxis and chemokinesis stimulation and also 
contributes to drug resistance (Garcia et al., 2006). In addition, the fast acting FGF 
mediates mitosis supporting the EGF action of cancer cell proliferation                      
(Fischer et al., 2008). The combination of growth factors and serum starvation could 
provide an insight of the mechanism of glioma cell adaptation to the new tumour    
micro-environment and indicate an increase in the expression of stem cell-related 
genes. 
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ii) Hypoxia  
Hypoxia is an important feature of solid tumours characterised by decreased oxygen 
availability and promoting tumour progression (Brahimi-Horn et al., 2007). The cells 
inhabited in the hypoxic environment show chemoresistance due to the limited supply 
of therapeutic drugs delivered via circulation (Cardone et al., 2005). Hypoxia activates 
hypoxia-induced alpha/beta (α/β) heterodimeric transcription factors (HIFs) leading to 
induction or repression of various genes related to angiogenesis, cell death/survival, 
pH regulation, metabolism, matrix remodelling and metastasis (Brahimi-Horn et al., 
2007 and Pouyssegur et al., 2006).  
 
Figure 1.7: Functions of HIF induced gene products. HIF α/β bound to the hypoxia-response 
elements mediates functions such as angiogenesis, metastasis, pH homeostasis, autophagy 
and metabolism via expression of various proteins. Regulated proteins include AMF autocrine 
motility factor; ANG-2 angiopoïetin-2; BNIP3 Bcl-2/adenovirus EIB 19 kDa-interacting protein 3; 
BNIP3L Bcl-2/adenovirus EIB 19 kDa-interacting protein 3 like; CA IX, XII carbonic anhydrase; 
CXCR4 cytokine (C-X-C motif) receptor 4; GLUT1 glucose transporter 1; LDH-A lactate 
dehydrogenase-A; LON, a mitochondrial protease; LOX lysyl oxidase; MCT1, 4, 
monocarboxylate transporter; MMP matrix metalloproteinase; NOXA pro-apoptotic member 
of Bcl-2 protein family; PDK1 pyruvate dehydrogenase kinase 1; REDD1/RTP801; VEGF vascular 
endothelial growth factor; VEGF-R1, vascular endothelial growth factor receptor (Adapted 
from Brahimi-Horn et al., 2007). 
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The behaviour of CSCs is affected by external signals that originate from the niche 
disrupting their regime of receptor mediated pathways (Li et al., 2009). HIFs are known 
to directly alter cellular differentiation and stem cell function (Keith and Simon, 2007). 
Cells under hypoxic conditions stabilise HIFs and trigger the activity of gene products 
such as Notch, Oct4, avian myelocytomatosis virus oncogene cellular homologue            
(c-myc; proto-oncogene), ABC transporters (ABC-T), and telomerase to promote a stem 
cell-like state (Fig 1.8). Furthermore, dedifferentiation and stem cell-like characteristic 
of self-renewal is promoted by factors such as KLF4 and Sox2 (Keith and Simon, 2007).  
Figure 1.8: Generation of stem cell induced by HIFs under hypoxic conditions (Adapted from 
Keith and Simon, 2007).  
Hypoxia-induced factor 2α (HIF2α; promotes tumorigenesis) has been reported to 
stimulate the expression stem cell marker protein CD133 in non-stem cells together 
with an up regulation of stemness related genes such as OCT4, homeobox protein 
NANOG (NANOG; self-renewal of undifferentiated stem cells) and c-Myc (Heddleston 
et al., 2009). The stem cell-like properties of CD133+ cells derived from glioblastoma 
were enhanced by reducing the optimum oxygen levels from 20 to 7 %, resulting in the 
simultaneous increase in the expression of other stem cell markers (nestin, Oct4 and 
SOX2) (McCord et al., 2009). The induction of hypoxia in glioma cells may provide an 
insight of the stem cell function of undifferentiation and self-renewal, respectively. 
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1.5 Focus of current research  
The main aim of the investigation entails an evaluation of stem cell-like features in the 
differentiated and undifferentiated cohort of brain tumour cells in order to define a 
suitable stem cell marker(s). U87-MG cells grown under normal cell culture conditions 
and those subjected to serum deprivation and hypoxia (undifferentiation) were initially 
checked for the expression of CD133, Oct4-A and BMP2 proteins. Flow cytometry 
provided detailed measurements of the quantitative expression, whereas 
immunofluorescence facilitated qualitative analysis of the candidate proteins. The cells 
were subsequently subjected to a chemosensitivity assay, cell cycle analysis and 
proteomic studies in order to achieve an in-depth understanding of the altered protein 
level within the undifferentiated glioma cells.   
1.5.1 Chemosensitivity 
Drug resistance remains one of the crucial attributes enabling stem cells to proliferate 
and repopulate even after the administration of effective chemotherapeutic drugs.         
In glioma, a high expression of multi-drug resistance genes such as MDR1 and multi-
drug resistance-associated protein-1 (MRP1) together with anti-apoptotic proteins 
such as permeability glycoprotein (P-gp), B-cell lymphoma 2 (B-cl2), Bcl-xL,             
FLICE-inhibitory protein (FLIP), cellular inhibitor of apoptosis-1 (c-IAP2), X-linked 
inhibitor of apoptosis protein (XIAP), neuronal apoptosis inhibitory protein (NAIP), and 
survivin in CD133+ cells has been associated with the chemoresistance mechanism      
(Bi et al., 2007; Shervington and Lu, 2008; Liu et al., 2006). Most of the 
chemotherapeutic drugs target the DNA affecting cell division to induce cell death. 
However, the DNA repair mechanism of CSCs helps to restore the integrity of the 
alkylated DNA bases following drug therapy failure (Johannesen et al., 2008). The 
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present study included exposure to chemotherapeutic drugs such as Temozolomide 
(TMZ) and Paclitaxel (Taxol) to test the drug resistant ability of the undifferentiated 
cells with respect to the control (differentiated) U87-MG cells. The effectiveness of the 
specified drugs was assessed by performing cell viability assay.  
 Temolozomide (TMZ) 
The drug, TMZ is a widely used anti-cancer agent in the treatment of various tumours 
due to its predictable bioavailabilty and minimal toxicity (Friedman et al., 2000). TMZ 
leads to cell death by inducing O6-guanine methylation creating cytotoxic lesions 
recognized by DNA mismatch repair (Gupta et al., 2006; Fig 1.9).  
 
 
Figure 1.9: Mechanism of action of TMZ. TMZ alkylates DNA at N-7/O-6 position of guanine 
residues to cause DNA damage (Adapted from http://cureglioma.info/). 
 
It is known that glioma cells demonstrate G2/M arrest in response to TMZ, whereas 
stem cells resist the effect with a down-regulation of autophagy-related proteins such 
as Beclin-1, autophagy protein 5 (Atg5) and light chain 3 (LC3) (Kanzawa et al., 2004 
and Fu et al., 2009). Therefore, if the cell is driven to an undifferentiated state 
populates a cohort of stem-like cells then they should exhibit resistance towards TMZ 
as compared to the control U87-MG cells. 
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 Paclitaxel (Taxol) 
Taxol is cytotoxic group of taxane that disrupts microtubule integrity                       
(Tseng et al., 1999). It affects the function of mitosis; cellular morphology and 
secretion by causing an arrest of the cell cycle in the G2/M phase                        
(Fruehauf et al., 2006). Cancer cells resist the cytotoxic effect of Taxol by taking 
advantage of the drug efflux mechanism with the help of P-gp                           
(Gottesman et al., 1993). Furthermore, Taxol alters the tubulin structure, deregulates 
the cell cycle, and also changes the drug binding affinity of the microtubules             
(Zhou et al., 2010).  
 
 
Figure 1.10: Stabilization of microtubules by Taxol in order to bring about mitotic arrest. 
(Adapted from http://course1.winona.edu/sberg/308s10/Lec-note/CytoskeletonA.htm). 
 
Since, CD133+ cells show a high expression of P-gp (Shervington and Lu, 2008); the 
existing group of undifferentiated stem cells inhabited within U87-MG cells may 
possibly indicate a resistance towards Taxol. 
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1.5.2 Cell cycle analysis 
A normal eukaryotic cell cycle comprises of four consecutive phases, i.e. G1, S, G2 and 
M phase. Chromosomal replication and separation occur in the S and M phase, 
whereas G1 and G2 phases represent the gap phase which favours cell growth. Stem 
cells have a unique cell cycle structure and control mechanisms that help to maintain 
the stem cell state (White and Dalton, 2006). Glioma stem cells display minimal DNA 
repair mechanism with an elongated cell cycle and enhanced basal activation of 
checkpoint proteins that may contribute to their radio resistance (Ropolo et al., 2009). 
Monitoring the cell cycle changes induced in the U87-MG cell line would explain the 
altered mechanism in their state of differentiation, under the influence of              
micro-environmental changes and administration of chemotherapeutic agents                    
(TMZ and Taxol). 
1.5.3 Proteomics 
Proteomics primarily involves the study and comprehensive analysis of proteins. In a 
population of stem cells, it helps to unravel the molecular mechanism of self-renewal 
and multi-lineage differentiation (Whetton et al., 2008). A complete developmental 
change in stem cells and its protein interactions cannot be examined by means of 
transcriptome analysis (Heck et al., 2007). Proteomics characterises and quantifies a 
range of proteins involved in drug resistance, signalling cascade, cell-to-cell 
interactions and membrane proteins that function as surface markers for cell 
identification (Zhang et al., 2010).   
Malignant gliomas show an increased concentration of soluble growth factors and 
cytokines which function to attract NSCs towards tumours (Heese et al., 2005). 
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Furthermore, a combined study using proteomics and microarray showed seven 
specific proteins namely Annexin A2 (ANXA2; receptor expressed on tumour cells), 
Tissue Inhibitor of Metalloproteinases-1 (TIMP-1), Collagen alpha-1(XI) (COL11A; 
malignancy), bax (Bax; anti- and pro-apoptotic regulator), Cluster of Differentiation 74 
(CD74; cancer metastasis), Tumour Necrosis Factor (ligand) Super Family, member 8 
(TNFSF8; Hodgkin lymphoma marker, cell proliferation/inhibition) and Serine 
palmitoyltransferase, long chain base subunit 2 (SPTLC2; associated with hereditary 
neuropathy type 1) to participate in the migration of stem cells towards malignant 
tumours (An et al., 2009). Analysis and quantification of post-translational 
modifications and investigation of pathways involved in embryonic stem cell (ESC) 
differentiation have been readily achieved through the proteomic approach       
(Whetton et al., 2008). In addition, it helps in the identification of novel 
protein/peptide markers on the cell surface which could be distinguished between two 
different cell lines with an equal potential.  
 The current research aims to investigate changes in protein expression of the 
differentiated (grown under normal cell culture conditions) and undifferentiated 
(serum-deprived and hypoxia) U87-MG cells using a proteomic approach. Proteins 
from the control and the treated samples were extracted and quantified in our 
laboratory and the rest of experimental protocol was carried out by Applied Biomics 
(U.S.A). The techniques used included Two-Dimensional Polyacrylamide Gel 
Electrophoresis (2D-PAGE), 2D Fluorescence Difference gel electrophoresis (2D-DIGE), 
DeCyder analysis, Mass spectrometry analysis and Mascot (Database search). The 
experiment resulted in differential, elevated and decreased dataset for the protein 
expression profile.  
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The protein dataset provided by the Applied Biomics (U.S.A) was then subjected to IPA 
(Ingenuity® Systems), Data mining and knowledge-based software to identify 
molecular functions and pathways which correlate with the protein datasets. Each 
protein was studied in detail in relation to the aspect of cell differentiation status and 
features of stemness.  
1.6 Previous studies from our laboratory 
Previous studies focused on the characterisation of CD133+ stem-like cells in glioma 
with respect to the expression of multi-drug resistance (MDR)-related molecules                  
(i.e. mdr1 and bcl-2). High levels of nestin, P-gp, Bcl-2, and telomerase in CD133+ 
astrocytoma/oligodendroglioma cells (GOS-3) and a significantly high expression of   
Bcl-2 at both the genotypic and phenotypic levels in CD133+ normal astrocytes 
compared to the autologous CD133- cells were observed (Shervington and Lu, 2008). 
The results indicated a possible contribution of MDR molecules to chemoresistance in 
CD133+ stem-like cells. It was concluded that Bcl-2 may play a crucial role in supporting 
the significant chemoresistance of CD133+ glioma and normal cells as compared to the 
corresponding CD133- cells. In addition, CD133+ glioma cells and CD133+ normal 
astrocytes share similar regulatory mechanisms with respect to the drug efflux protein 
P-gp, the anti-apoptotic protein Bcl-2 and the immortalisation protein telomerase 
(Shervington and Lu, 2008).    
The use of serum deprivation (without supplements) enriched the CD133+ cells in 
astrocytoma/oligodendroglioma (GOS-3) cells with nestin, mdr1 and bcl-2 proteins and 
down-regulated hTERT, bmi1, c-myc and telomerase activity. Thus, a first direct link 
between CD133 and other molecules e.g. mdr1, bcl-2, hTERT, bmi1, and c-myc was 
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provided. Serum deprivation also highlighted that CD133+ originated from secondary 
glioblastomas, putting forward a query on its derivation from a NSC, progenitor or a 
differentiated glioma cell (Lu, 2008).   
Based on the above data, the current study focused on evaluating the differentiated 
and undifferentiated state of glioma cells for stem cell-like traits. Glioma cells grown 
under normal cell culture conditions were considered as differentiated cells since they 
arise from a process of differentiation from stem cell progeny (Sell, 2006). On the 
other hand, the undifferentiated state of the differentiated glioma cells was achieved 
by induction of two independent micro-environmental changes (hypoxia and serum 
deprivation) (Fig. 1.11). The present study mainly focused on the regulation of the 
proteins CD133, Oct-A and BMP2 and the cell cycle phase when the brain tumour cells 
were driven from a differentiated to an undifferentiated state. In addition, the 
chemosensitivity assay performed may provide an insight into the drug resistance 
potential of the undifferentiated glioma cells. 
 
                                                           
                                                                            
 
 
 
Figure 1.11: Differentiation and undifferentiation of cells. (Adapted from 
http://www.allthingsstem cell.com/wp-content/uploads/2009/09/p53_cancer_cell_formation-
copy2.png) 
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1.7  U87-MG cell line to evaluate stemness status 
Previous data from our laboratory have demonstrated the isolation of CD133 from 
astrocytoma/oligodendroglioma cells (GOS-3) (Lu 2008, PhD thesis). In the present 
study, U87-MG (grade IV) being the highest form astrocytic brain tumour cell line was 
used for all the experiments. These cells have been widely used as an in-vitro model of 
human glioblastoma cells to study the cytotoxic effect of chemotherapeutic drugs 
towards cancer cells. In 2008, Yu et.al demonstrated that U87-MG cells inhabited a 
fraction of neurosphere forming cells with a capability of self-renewal and 
multipotency. Similar to CSCs, these cells showed histological features identical to 
glioblastoma together with cellular pleomorphism, hyperchromatic nuclei, 
pseudopalisades surrounding necrosis, high density of micro vessels and invasion to 
the brain parenchyma (Yu et. al., 2008). In addition, U87-MG cells elicit receptors for 
CD133 and epidermal growth factor receptor vIII (EGFRvIII). A biphasic antibody 
directed against CD133+ and EGFRvIII+ has been successful as a therapeutic agent for 
specifically targeting CD133+/EGFRvIII+ cancer stem cells (Wong et. al., 2009). Vascular 
endothelial growth factor (VEGF) has been a vital factor in promoting angiogenesis in 
glioma. U87-MG cells when subjected to hypoxia, displayed an aggressive growth with 
an up-regulation of VEGF by means of transient receptor potential cation channel 1 
(TRPC1) (Wang et. al., 2009). Some of the characteristics of U87-MG cells resemble to 
CSCs, and thus, it was decided to use it as a suitable target under differentiated and 
undifferentiated conditions in order to study the stem cell-like properties. 
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1.8 Questions to be addressed concerning the investigation (Working 
Hypothesis) 
1. Is CD133 a reliable glioma stem cell marker? 
2. Should the research focus on the differentiated and undifferentiated aspects of 
glioma cells in order to trace stemness properties? 
3. What would be the requirements of desired glioma stem cell marker/s? 
1.8.1 Main Aim 
1. To address the complexity of identifying glioma stem cell biomarker. 
1.8.2 Specific Aims 
The specific aims of this study were: 
1. To evaluate the expression of CD133, Oct4-A and BMP2 in differentiated and 
undifferentiated glioma cells. 
2. To study the proteomic change influenced by hypoxia and serum deprivation.  
 
1.8.3 Novelty of the current research project 
1. The current research focuses on exploring the undifferentiated and differentiated 
aspects of brain tumour cells in order to define CSCs. 
2. Introduction of pluripotency factor of Oct4-A in glioma and checking its expression 
as a potent CSC marker with respect to CD133. 
3. Studying the proteomic changes on account of hypoxia and serum deprivation 
(undifferentiation) in order to obtain an insight into the deregulated pathways in 
glioma. 
4. Propose selective marker/s for the detection of glioma stem cells. 
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2.1 Cell Culture 
2.1.1 Cell lines  
The experiments were carried out using different grades of human glioma cell lines 
(Table 2.1) with Grade I astrocytoma expressing a mutant p53 (1321N1), a grade II/III 
astrocytoma/ oligodendroglioma (GOS-3) and a grade IV glioblastoma (U87-MG). The 
human cell lines were purchased from the European Collection of Cell Cultures (ECACC) 
and the American Type Culture Collection (ATCC) with no evidence of the presence of 
infectious viruses or toxic products. The handling instructions were followed as 
recommended by the Advisory Committee on Dangerous Pathogens (ACDP) for 
Category 2 containment.  The cells were received as frozen ampoules in 1 ml plastic 
cryotubes in an appropriate freezing medium. The freezing medium was supplemented 
with 10 % foetal bovine serum (FBS), 2 mM L-glutamine and 10 % (v/v) dimethyl 
sulphoxide (DMSO). Cells were grown by incubating at 37 °C in a humidified 5 % CO2 
atmosphere and maintained in 75 cm2 or 25 cm2 tissue culture-treated polystyrene 
flasks (Sigma, UK) as monolayer cultures. All cells were harvested when they reached 
70-80 % confluence. 
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Table 2.1: Cell lines used and their media formulation. 
Cell lines         Description           WHO grade Culture Media Suppliers 
1321-N1          Astrocytoma II DMEM, 10 % (v/v) FBS, 2 mM              
L-glutamine 
ECACC, UK 
              GOS-3 Astrocytoma/Oligodendro-                                                                                                       
glioma 
II/III DMEM, 10 % (v/v) FBS, 4 mM             
L-glutamine 
DSMZ, Germany 
 
 
            U87-MG                                   Glioblastoma                                   IV   
EMEM, 10 % (v/v) FBS, 2 mM                     
L-glutamine, 1 % (v/v)                      
non-essential amino acid 
             ECACC, UK 
RHB-A®, 20 ng/ml EGF, 
20 ng/ml FGF 
             ECACC, UK 
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2.1.2 Media and reagents  
Media preparations were carried out under aseptic conditions by the addition of 
required supplements as recommended by the suppliers (Table 2.2). The prepared 
medium was labelled with the date of preparation and stored at 4 °C. Serum-free basal 
medium (RHB-A) was foil-wrapped to protect from light as it contained light-labile 
components. The reconstituted medium was stable for 4 weeks.  
The volume of the supplement that was to be added was calculated using the formula: 
                                                    V1 C1 = V2 C2 
                                                         V1 = V2 C2 
                                                                    C1 
 
Where: V1 = Initial volume 
C1 = initial stock concentration 
V2 = final volume 
C2 = final concentration 
This formula was adopted to determine volume and concentrations in appropriate 
calculations throughout this study.  
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Table 2.2: Media, reagents, supplements and storage conditions 
             Reagents 
Abbreviation &        
storage temp     
           Formulations     Suppliers 
Dulbecco’s modified 
eagle’s medium 
     DMEM, 
      2-8 oC 
25 mM hepes, 1.0 g/l glucose 
1.0 mM sodium bicarbonate, 
0.011 g/l phenol red 
       
      Sigma, UK 
Eagle’s minimum 
essential medium 
     EMEM, 
      2-8 oC 
2.0 g/l sodium bicarbonate 
4.5 g/l glucose, 10 mM hepes 
1.0 mM sodium pyruvate, 
0.0053 g/l phenol red 
       
      Sigma, UK 
Serum free basal medium 
     RHB-A®,  
       2-8 oC 
Company patency       Stem cell                                        
sciences, UK 
Foetal bovine serum   FBS,  -20 oC Heat inactivated FBS     GIBCO, UK 
L-glutamine       -20 oC 200 mM L-glutamine      Sigma, UK 
Non essential amino acid        2-8 oC 100 x non essential amino acid      Sigma, UK 
Phosphatase buffer saline 
(PBS, 1x) 
        2-8 oC 8 g/l NaCl, 0.2 g/l KCl, 
1.44 g/l Na2HPO4 
0.24 g/l KH2PO4, pH 7.4 
     
       BDH, UK 
Trypan blue (0.4 %) 
       Room 
temperature 
0.81 % sodium chloride 
0.06 % potassium phosphate, 
dibasic 
    
     Sigma, UK 
Dimethyl sulfoxide 
DMSO, Room 
temperature 
99.5 % dimethyl sulfoxide, 
0.81 % sodium chloride 
 
      Sigma, UK 
Recombinant Human 
Epidermal growth factor 
 hEGF,  -20 oC Recombinant (E.coli) BD Biosciences,                                              
           UK 
Basic Fibroblast 
growth factor 
 bFGF,  -20 oC Recombinant (E.coli) BD Biosciences,  
           UK 
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2.1.3 Resuscitation of frozen cells  
The cell lines supplied were stored in cryotubes in liquid nitrogen. The protocol was 
carried forward as recommended by ECCAC. The medium was pre-warmed at 37 °C in 
a water bath for approximately 30 min. The external surfaces of the media bottle were 
decontaminated with 70 % ethanol and then transferred to a sterile field. Frozen cell 
cryotubes were completely thawed by placing them in a water bath at 37 °C for 1-2 
min. The contents of the cryotube were then resuspended in 4 ml of appropriate 
media in a 15 ml centrifuge tube. The resuspended cells were then centrifuged at    
150 x g for 5 min at room temperature. The supernatant was discarded and the cell 
pellets were aliquoted into 25 cm2 tissue culture-treated polystyrene flasks with 5 ml 
of medium in each flask. The flasks were gently shaken back and forth manually to 
enhance equal distribution of the cells within the medium and were labelled with the 
name of the cell line, passage number and date. The cells were then incubated at 37 C 
in 5 % CO2 and 95 % oxygen and the medium was changed every alternate day. For 
slow growing cells the medium was changed after every 48 hours of incubation to 
maintain sufficient nutrient levels for the cells. Cells were observed under the 
microscope after overnight incubation. 
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2.1.4 Subculture and cell treatment 
i) Subculture  
When the monolayer of the cells reached 70-80 % confluence, they were scraped to 
enable sub-culture. The cells were washed 3 times with PBS (0.5 ml, pH 7.4, 37oC) to 
remove excess culture media and then were scraped using a sterile disposable scraper. 
To ensure approximately 95 % cell detachment, the cells were observed under the 
microscope. The cells were re-suspended in 8 ml of media and transferred into a 15 ml 
centrifuge tube. A 20 µl suspension was taken for a cell count and the remaining cells 
were centrifuged at 1000 rpm (112 g) for 5 min. The cell pellets were re-suspended in 
growth media in a new flask seeding at 2-4 x 10,000 cells/cm2 for cancer cells (1321N1, 
GOS-3, U87-MG). The flasks were suitably labelled with the name of the cell line, 
passage number and date and then incubated under ordinary culture conditions. 
ii) Cell treatment (hypoxia and serum deprivation) 
Hypoxia and serum deprivation were implemented to study the cell differentiation 
status. 
a. Hypoxia  
U87-MG cells (70-80 % confluence) were subjected to 100 % nitrogen for 30 
min (previously optimised technique in our laboratory) under sterile conditions 
to enhance undifferentiation (Lu, 2008, PhD thesis). The cells were incubated 
for 24 hours under cell culture incubation conditions and later scraped and 
used for further experiments. 
b. Serum deprivation  
U87-MG cells (70-80 % confluence) were replaced with serum free RHB-A® 
media supplemented with 20 ng/ml of hEGF and bFGF, respectively. The cells 
were observed for morphological changes within 3-5 days after which the cells 
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transformed completely into neurospheres, indicating their undifferentiation 
state. The media was replaced with supplements every alternate day. The 
hypoxia-treated and the serum-deprived cells were then subjected to multiple 
experimental procedures which included flow cytometry, cell viability and cell 
cycle analysis. 
 
2.1.5 Cryopreservation 
The cell pellets after scraping were alternatively cryopreserved for future use. 1 x 106    
cells were re-suspended in a cell freezing medium (complete culture medium with 10 
% DMSO) in 1 ml cryoprotective ampoules, labelled with the cell line name, passage 
number and date. The ampoules were then placed in a ‘Mr. Frosty’ freezing container       
(Nalgene, UK) filled with isopropanol, stored at -80oC overnight and then transferred 
into -195 °C liquid nitrogen container. For mRNA isolation 2  106 cells were frozen and 
stored as pellets at -80 °C without the freezing medium. Cells required for 
immunofluorescence were cultured in chamber slides and fixed with 
paraformaldehyde. In order to carry out cell cycle analysis a pellet containing 1  106   
cells was washed once with PBS and then fixed by re-suspending them in 70 % ice cold 
ethanol. These fixed cells were stored for a minimum of 24 hours at -20 °C before 
following the cell cycle analysis protocol. For the waste disposal as recommended by 
ECCAC, the culture medium, pipette and tips were placed in 1 % Virkon solution 
(Anachem Ltd, UK) overnight before being autoclaved and incinerated.  
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2.1.6 Cell library maintenance  
Cell library was maintained to manage cell stocks of different cell lines. A data entry log 
book was maintained having a record of the position of storage of cryotubes in the 
liquid nitrogen. This allowed easy traceability of specific cells for future reference. The 
level of liquid nitrogen was monitored regularly to ensure an appropriate 
cryopreservation. 
 
2.1.7 Quantification of cells and cell viability using a haemocytometer 
Cell aliquot (20 µl) was diluted 1:1 with trypan blue (Freshney, 1987) to identify the 
number of viable cells. A cover slip was attached to the haemocytometer to create 
Newton’s refraction rings. Both sides of the chamber were filled with the stained cell 
suspension and the cells were counted under a light microscope using x 20 
magnification. Cell viability was calculated as a percentage using the following 
equation: 
 
      Total number of cells counted/ml = total viable cells + total dead cells x 104 
             Percentage of viable cells =     viable cells       x   100      
                                                              Total cell number 
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2.2 Messenger RNA (mRNA) isolation and quantification 
mRNA from cell lines was extracted using an mRNA Isolation Kit (Roche, UK) according 
to the Manufacturer’s instructions provided. The isolation kit worked on the basis that 
the poly (A)+ tail of mRNA hybridised to a biotin-labelled oligo (dT)20 probe. A 
Streptavidin-coated magnetic particle captured the biotinylated hybrids and by means 
of a magnetic separator, the magnetic particles were captured.  The fluid was then 
removed by washing the particles with the washing buffer and finally the mRNA was 
eluted from the particles by incubation using redistilled water. This method enabled to 
achieve a highly purified form of mRNA without the preparation of total RNA. Table 2.3 
shows the reagents used in the process of mRNA isolation and figure 2.1 illustrates the 
principle of mRNA isolation. 
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Figure 2.1: Schematic representation of the principle of mRNA isolation (Roche diagnostic, 
UK). (Modifiedfromhttp://www.roche-applied science.com/US/ProdInfo/images/ mrna_ 
isolation _kit_flow01n.jpg) 
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2.2.1 mRNA isolation  
The sample and reagents employed in this study were kept on ice throughout the 
isolation protocol. A total of 2 × 106 cells was washed three times using ice cold 1 x PBS 
and was resuspended with 500 µl lysis buffer. Cells were then sheared mechanically by 
passing six times through a 21 gauge needle to prepare a cell lysate. 0.5 µl of biotin-
labelled oligo (dT)20 probe was added to the lysate and allowed to hybridise with 
mRNA at 37 °C for 5 min. Simultaneously, streptavidin magnetic particles were 
prepared as follows: they were resuspended thoroughly before appropriate amount of 
magnetic particle (Table 2.3) was transferred to a fresh microcentrifuge tube. Using a 
magnetic separator the Streptavidin magnetic particles were separated from its 
storage buffer. Storage buffer was discarded and the particles were then washed once 
in 75 μl of lysing buffer to remove any excess storage buffer. The supernatant was 
again discarded and the particles were resuspended in the dT-mRNA hybrid mixture 
and incubated at 37 °C for 5 min to attain immobilisation. The hybrid-linked particles 
were magnetically separated from the fluid and the supernatant was discarded. 
Magnetic particles were then resuspended thrice in washing buffer (3 × 200 µl) in 
order to remove all contaminants quantitatively. Subsequent to the final wash, the 
supernatant was discarded and the mRNA was eluted from the magnetic particles by 
the addition of 10 μl redistilled water. This was followed by an incubation at 65 °C for 2 
min. mRNA was separated from the magnetic beads using a magnetic separator. The 
supernatant containing the mRNA was analysed quantitatively stored at -20 °C in an 
RNAse free eppendorf tube. The mRNA isolated was further transcribed into single-
stranded cDNA to perform PCR.                                   
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Table 2.3: reagents used in this study for mRNA isolation  
Reagents Preparation Contents 
2 x 105 
cells 
2 x 106 cells 
PBS Autoclaved 1x, pH 7.4, ice cold 3 x 500 µl 3 x 500 µl 
Lysis buffer 
Used from the 
kit (Roche , UK) 
Stored at 2-8 oC 
0.1 M Tris buffer  
0.3 M LiCI 
10 mM EDTA  
1 % lithium dodecylsulfate  
5 mM DTT (dithiothreitol) 
pH 7.5 
0.1 ml 0.5 ml 
Streptavidin 
magnetic 
particles 
10 mg/ml in 50 mM hepes 
0.1 % bovine serum albumin 
0.1 % chloracetamide 
0.01 % methylisothiazolone, 
pH 7.4 
50 µl 50 µl 
Oligo(dT)20 
probe, biotin 
labelled 
100 pmol biotin-labelled 
oligo(dT)20 per µl of 
redistilled water 
0.5 µl 
(50 pmol) 
0.5 µl 
(50 pmol) 
Washing buffer 
10 mM Tris buffer 
0.2 M LiCI 
1 mM EDTA 
pH 7.5 
3 x 200 µl 3 x 200 µl 
Redistilled 
water 
RNase-free 5 µl 10 µl 
 
 
 
55 
 
2.2.2 mRNA quantification 
The mRNA was quantified spectrophotometrically using a Helios gamma 
spectrophotometer (Thermo spectronic, UK) by measuring the absorbance at 260 nm 
(A260) and 280 nm (A280).  
The Isolated mRNA was diluted 1: 250 1 x Tris-Acetate-EDTA (TAE) buffer. The optical 
density (OD) of the diluted mRNA sample was measured using the absorbance reading 
taken at 260 nm. A blank containing 2 μl of dH2O and 498 μl 1x TAE buffer was used as 
reference for each sample. 
Concentration of extracted mRNA was calculated using the formula:                              
An emission of one OD (One A260 unit) = 40 μg/ml for single-stranded (ss) mRNA. 
Dilution factor = 250 
Concentration of mRNA (µg/ml) = A260 x 250 x 40  
A ratio of A260/A280 represents the level of contamination (e.g. protein) in a RNA 
sample. A260/A280 > 1.8 - 2.0 suggested a pure preparation of (ss) mRNA.  
 
 
 
 
 
 
56 
 
2.3 Introduction to bioinformatics 
Application of computer science and statistics to molecular biology is termed as 
bioinformatics. Bioinformatics by means of multiple disciplines such as mathematics, 
artificial intelligence, computer science, chemistry, biochemistry, and statistics helps to 
facilitate data analysis. The ease of data analysis not only provides an insight of the 
various biological processes but also addresses many unanswered biological questions 
(Kim, 2000). 
The subject areas covered under this field range from structural biology, genomics to 
gene expression studies and assists in storing and organizing data. It provides 
specialized tools to view and analyze the explosive data generated by biological 
scientists throughout the world (Kim, 2000). The World Wide Web has become an 
essential feature to the world of bioinformatics as it makes DNA, RNA and protein data 
available to users throughout the world through databases such as National Centre for 
Biotechnology Information (NCBI), GenBank (USA), European molecular biology 
laboratory (EMBL) (Europe) (Fenstermacher, 2005). The present achievements of 
bioinformatics hold substantial promise to transform the medical world. 
2.3.1 Gene sequence and location  
In the present study, bioinformatics was used to locate the genes of interest among 
the human DNA sequences. Location of the target genes with it diagrammatic 
representation was obtained online with the help of GeneCards® (Weizmann Institute 
of Science, http://www.genecards.org/). GeneCards® is an integrated database of 
human genes providing a concise integrated summary on various genes, extracted 
from major public and proprietary database. A gene annotation from over 40 mined 
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resources can be managed using GeneCards® (Shmueli et al., 2003). The whole 
template DNA sequence of target genes was found online at National Center for 
Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) which provides the 
GenBank DNA sequence database. 
For this study genes without any identified mutation were chosen for the design of 
sequence-specific primers (required for qRT-PCR) using Primer3 software. Primer3 
software helps to choose oligonucleotide primers for the template DNA sequence as 
also displays information about the sequences and  average length of the primer, 
amplicon size, melting temperature (Tm) and GC content (GC%). 
 
2.3.2 Primer design 
The primer used for a PCR commercially synthesised single-stranded oligonucleotide 
having a short length of 18 to 22 bp.  Primers used in the technique of PCR amplified 
the gene of interest. The following parameters were generally taken care of while 
designing primers for a PCR to give yields of the specific amplicon: 
a. A primer should be between 18 to 22 bp. Long primers having longer annealing 
temperatures are more specific, but their efficiency is low because 
thermodynamically the annealing takes longer. 
b. G/C and A/T content of the primer should be similar to or higher than that of 
the sequence to be amplified.  For example, a primer, which is 20 nucleotides 
long, normally corresponds to 45-55 % GC content. Therefore its melting 
temperature should be between 55 and 65oC (Dieffenbach et al., 1993).  
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Primers with melting temperatures above 65oC have a tendency for secondary 
annealing. Within a primer pair, the GC content and Tm should be well matched. Poorly 
matched primer pairs could prove to be less efficient and non-specific because loss of 
specificity arises with a lower melting temperature (Tm). Thus, PCR primers should 
maintain a reasonable GC content. Oligonucleotides 20 bases long with a 50 % G + C 
content generally have a melting Tm values in the range of 52-58 
oC offering a sufficient 
thermal window for efficient annealing (Dieffenbach et al., 1993). Figures 2.2, 2.3, 2.4 
and 2.5 represents the output from gene locations and primer designs for CD133, 
Oct4-A, BMP-2 and GAPDH, respectively. Primer 3 was accessed from:   
http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi. 
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A.  
 
 
 
B. 
 
 
C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Bioinformatic data generated for prominin 1 (CD133). (A) Diagrammatic 
representation of the CD133 locus on chromosome 4p15.32 (NCBI). (B) CD133 gene location on 
its respective human chromosome denoted by red bar (GeneCards database). (C) Output page 
generated from Primer 3 for CD133 (Primer 3). 
CD133 Primer3 Output 
Using 1-based sequence positions 
OLIGO       start len    tm    gc%   any    3'  Primer sequence  
LEFT PRIMER  61   20   60.00  55.00  3.00  0.00 gccagcctcagacagaaaac 
RIGHT PRIMER 308  20   59.97  55.00  5.00  2.00 ccaagccttaggagcatctg 
SEQUENCE SIZE: 3857 
INCLUDED REGION SIZE: 3857 
 
PRODUCT SIZE: 248, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
     
      gccagcctcagacagaaaactgaagattcagcagatccagtgcttcctgctcctcttctg 
      >>>>>>>>>>>>>>>>>>>>                                         
 
      cccaggaacacgcttgccttccccaaggcttccagaagctctgaggcaggaggcaccaag 
                                                                   
 
      ttctacctcatgtttggaggatcttgctagctatggccctcgtactcggctccctgttgc 
                                                                   
 
      tgctggggctgtgcgggaactccttttcaggagggcagccttcatccacagatgctccta 
                                                      <<<<<<<<<<<< 
 
      aggcttgg 
               <<<<<<<< 
Key:       >>>>>> - Left / (sense) forward primer binding site  
<<<<<< - Right / (anti-sense) reverse primer binding site 
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Figure 2.3: Bioinformatic data generated for Octamer 4    (Oct4-A). (A) Diagrammatic 
representation of the Oct4-A locus on chromosome 6p21.31 (NCBI). (B) Oct4-A gene location 
on its respective human chromosome denoted by red bar (GeneCards database). (C) Output 
page generated from Primer 3 for Oct4-A (Primer 3). 
 
 
Oct4-A Primer3 Output 
Using 1-based sequence positions 
OLIGO       start len  tm    gc%   any    3'  Primer sequence  
LEFT PRIMER   8    19 60.07 52.63  3.00  0.00 gacacctggcttcggattt 
RIGHT PRIMER 181   19 60.88 57.89  3.00  3.00 gaatcccccacacctcaga 
SEQUENCE SIZE: 186 
INCLUDED REGION SIZE: 186 
 
PRODUCT SIZE: 174, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 2.00 
 
  
 gacacctggcttcggatttcgccttctcgccccctccaggtggtggaggtgatgggccagggg 
 >>>>>>>>>>>>>>>>>>>                                   
 
 ggccggagccgggctgggttgatcctcggacctggctaagcttccaaggccctcctggagggc 
                                                                   
 
 caggaatcgggccgggggttgggccaggctctgaggtgtgggggattc 
                              <<<<<<<<<<<<<<<<<<< 
 
 
 
Key:       >>>>>> - Left / (sense) forward primer binding site  
<<<<<< - Right / (anti-sense) reverse primer binding site 
 
   
      
 
 
 
 
Key:       >>>>>> - Left / (sense) forward primer binding site  
<<<<<< - Right / (anti-sense) reverse primer binding site 
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Figure 2.4: Bioinformatic data generated for Bone morphogenetic protein 2    (BMP2). (A) 
Diagrammatic representation of the BMP2 locus on chromosome 20p12 (NCBI). (B) BMP2 gene 
location on its respective human chromosome denoted by red bar (GeneCards database). (C) 
Output page generated from Primer 3 for BMP2 (Primer 3). 
BMP2 Primer3 Output 
OLIGO        start len   tm    gc%   any    3'  Primer sequence   
LEFT PRIMER  5605  20   59.99 55.00  2.00  1.00 cccagcgtgaaaagagagac 
RIGHT PRIMER 5772  20   60.01 60.00  6.00  3.00gagaccgcagtccgtctaag 
SEQUENCE SIZE: 19166 
INCLUDED REGION SIZE: 19166 
 
PRODUCT SIZE: 168, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
  tgaaaagagagactgcgcggccggcacccgggagaaggaggaggcaaagaaaaggaacggacat 
  >>>>>>>>>>>>>>>>>>>>                 
 
  tcggtccttgcgccaggtcctttgaccagagtttttccatgtggacgctctttcaatggacgtg 
                                                                    
 
  tccccgcgtgcttcttagacggactgcggtctccta 
               <<<<<<<<<<<<<<<<<<<<< 
 
 
    Key:       >>>>>> - Left / (sense) forward primer binding site  
<<<<<< - Right / (anti-sense) reverse primer binding site 
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Figure 2.5: Bioinformatic data generated for glyceraldehyde-3-phosphate dehydrogenase    
(GAPDH). (A) Diagrammatic representation of the GAPDH locus on chromosome 12p13 (NCBI). 
(B) GAPDH gene location on its respective human chromosome denoted by red bar (GeneCards 
database). (C) Output page generated from Primer 3 for GAPDH (Primer 3). 
GAPDH Primer3 Output 
Using 1-based sequence positions 
OLIGO       start len   tm    gc%    any    3'   Primer sequence  
LEFT PRIMER 1440  20  60.01   55.00  5.00  2.00  accagcctctggcttctaca 
RIGHT PRIMER1633  20  60.01   60.00  4.00  0.00  ccctagctgtgtgccttctc 
SEQUENCE SIZE: 10880 
INCLUDED REGION SIZE: 10880 
 
PRODUCT SIZE: 194, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 0.00 
 
 
                                                                  
 accagcctctggcttctacagcctcagacaatgactttgtcacaccagagccccgccgtactaccc 
 >>>>>>>>>>>>>>>>>>>>                                          
  
 gtcggcatccaaacacccagcagcgagcttccaaaaagaaacccaaagttgtcttctcaagtagtg 
                                                                   
 
 atgagtccagtgaggaaggtatgatgctcccgcctgttcccggccgagaaggcacacagctaggg 
                                                <<<<<<<<<<<<<<<<<<                                                
 
 
Key:       >>>>>> - Left / (sense) forward primer binding site  
<<<<<< - Right / (anti-sense) reverse primer binding site 
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2.4 Complementary DNA (cDNA) synthesis 
An amount of 100 ng of isolated mRNA was reverse transcribed to cDNA using a 1st 
Strand cDNA Synthesis Kit (Roche, UK). Figure 2.6 showed the principle of converting 
mRNA to cDNA while table 2.4 enlisted the reagents with its formulations provided in 
the 1st Strand cDNA Synthesis kit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Principle of Reverse transcription of mRNA to cDNA. (Modified from http://  
8e.devbio.com/images/ch04/0405fig2.jpg)
REVERSE TRANSCRIPTION 
(cDNA synthesis) 
 
 
( 
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Table 2.4: Reagents used for cDNA synthesis  
 
Reagents 
Formulation & 
concentrations 
Volume of reagents 
(Final volume: 20 
µl) 
Final 
concentrations 
10x Reaction buffer 
100 mM Tris, 
500 mM KCl, 
pH 8.3 
2 µl 1  x 
MgCl2 25 mM 4 µl 5 mM 
Deoxynucleotide mix 
dATP, dCTP, 
dTTP, dGTP-, 
10 mM 
2 µl 1 mM 
Oligo-p(dT)15 primer 
0.02 A260 units/µl 
(0.8 µg/µl) 
2 µl 
0.04 
A260 units 
(1.6 µg) 
RNase inhibitor 50 units/µl 1 µl 50 units 
AMV reverse 
transcriptase 
- - - - - 0.8 µl  20 units 
Sterile water - - - - - 
20 µl – 11.8 µl – 
mRNA sample volume 
- - - - - 
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2.4.1 cDNA synthesis protocol  
An amount of 50 - 100 ng of mRNA was required for successful cDNA synthesis. 
Therefore, 100 ng of isolated mRNA was used to obtain cDNA in this study. Samples 
and reagents were kept on ice throughout the cDNA preparation. All reagents were 
thawed on room temperature except for RNase inhibitor and AMV reverse 
transcriptase which were thawed on ice. A mixture containing all the reagents was 
prepared to sum up to a total volume of 11.8 µl (volume as mentioned in table 2.4). An 
appropriate volume of mRNA sample was added to the mixture based on its 
quantification value to achieve a final concentration of 100 ng. Sterile water was added 
to obtain a final volume of 20 µl in each sample and the mixture was briefly vortexed 
and centrifuged. The mixture was incubated at 25 °C for 10 min to allow mRNA and 
primer annealing. The mRNA template was reverse transcribed into single-stranded 
cDNA by further incubating the mixture at 42 °C for 60 min. AMV reverse transcriptase 
was denatured by incubating the reaction at 99 oC for 5 min and then further cooled at 
4 oC for 5 min. The synthesised cDNA was stored at at -20 oC until required. 
2.5 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was a technique used detect the genetic expression of the targeted mRNA. 
This was a sensitive and simple technique that logarithmically amplified a short 
sequence of DNA (100-600 bases) within a longer double stranded DNA/cDNA 
molecule. The level of CD133, OCT4A, BMP2 and GAPDH expressions was calculated by 
qRT-PCR using the Light Cycler 2.0 system. (Roche Diagnostics, UK) and Light Cycler® 
Fast Start DNA MasterPLUS SYBR Green I kit according to the manufacturer’s 
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instructions. Prior to the study the PCR of each targeted gene was optimised. Figure 
2.7 illustrated the basic steps of denaturation , annealing and extension in a PCR. 
 
  
Figure 2.7: Steps involved in a PCR. Denaturation of double-stranded DNA into two 
complementary single strands at 95oC, annealing of the primers P1 and P2 to the target region 
of DNA at about 56 oC (temperature varies according to the primers used) and extension of the 
primers from 3 prime to the 5 prime direction at 72 oC by DNA polymerases. (Modified from 
http://www.flmnh.ufl.edu/cowries/PCR.gif ). 
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Table 2.5: Reagents provided in the PCR kit (Roche, UK) and volume of reagents 
required to make PCR master mix. 
Kit reagents 
Reagents                     Compositions Quantity 
Light Cycler® Fast Start 
Enzyme (1a) 
Fast Start Taq DNA Polymerase 1 vial 
Light Cycler® Fast Start 
Reaction Mix SYBR Green (1b) 
Reaction buffer, dNTP mix (with dUTP instead 
of dTTP), SYBR Green I dye and 10 mM MgCl2 
3 vials 
H2O, PCR-grade RNase-free H2O 2 ml 
PCR master mix (total =20µl) 
PCR primer mix Left + right primer (1:1) 2 µl 
Enzyme Master Mix 
 
14µl of  Light Cycler® Fast Start Enzyme (1a) 
added to Light Cycler® Fast Start Reaction Mix 
SYBR Green (1b) 
4 µl 
Single-stranded cDNA 
template 
--------- 2 µl 
H2O, PCR-grade ---------- 12 µl 
 
 
2.5.1 Primer Preparation  
Each primer (right/sense and left/antisense) was dissolved in 250 µl of molecular 
biology grade water to obtain 20 µM stock solutions and stored at -20oC as 
recommended by the manufacturer. Table 2.6 represented the specific primer sequence 
of the targeted genes and their specific annealing temperature.
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Table 2.6: Primer sequence and the annealing temperature of the targeted genes 
 
Wallace rule(GC/AT rule): calculates the  primer annealing temperature for short DNA oligo consisting of 14-20 base pairs: T = 2oC(A + T) + 4oC (G + C), where A, C, 
G and T represent the number of adenine, cytosine, guanine and thymine bases in each primer sequence, respectively (Wallace et al., 1979).
Gene Primer Sequences 
 
Product size 
(bp) 
Annealing Temperature (oC) 
Primer3 
TIB 
MOLBIOL 
Wallace rule* 
Experimental 
Temperature 
after optimisation 
 
CD133 
Sense:              
5′ -TTGTGGCAAATCACCAGGTA-3′    
Antisense:  
5′ -TCAGATCTGTGAACGCCTTG-3′  
248 
59.96 
59.98 
55.80 
55.50 
58.00 
60.00 
64.00 
64.00 
Oct4-A Sense:              
5′ -GACACCTGGCTTCGGATTT-3′    
Antisense:  
5′ -GAATCCCCCACACCTCAGA-3′  
174 Self designed 
56.5 
56.3 
58.00 
60.00 
56.00 
56.00 
BMP-2 Sense:              
5′ -CCCAGCGTGAAAAGAGAGAC-3′    
Antisense:  
5′ -GAGACCGCAGTCCGTCTAAG-3′  
168 
59.99 
60.01 
56.5 
56.3 
62.00 
64.00 
56.00 
56.00 
GAPDH 
Sense:                                       
5′ -GAGTCAACGGATTTGGTCGT- 
3′     
Antisense:  
5′ -TTGATTTTGGAGGGATCTCG- 3′    
194 
59.83 
59.99 
56.20 
54.80 
60.00 
58.00 
56.00 
56.00 
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2.5.2 PCR protocol  
All reagents and samples were kept on ice throughout the experiment. The PCR 
enzyme reaction mix was prepared by adding 14 µl of Light Cycler® Fast Start Enzyme 
(1a) to Light Cycler® Fast Start Reaction Mix SYBR Green vial (1b). The prepared enzyme 
was then labelled and stored at 2-8 °C and it was also protected from light. PCR master 
mix was prepared by adding 12 µl molecular biology-grade H2O, 2 µl of 10 µM PCR 
primer mix, 4 µl of Master Mix and 2 µl single-stranded cDNA template to give a total 
volume of 20 µl. PCR grade H2O was substituted for cDNA to serve as a negative 
control for the experiment. The protocol involved hot-start induction, with the Fast 
Start Taq DNA polymerase enzyme activated by pre-incubating the reaction mixture at 
95 oC for 10 min. Hot start induction was crucial in this method to prevent non specific 
elongations and thus increased PCR specificity, sensitivity and yield                      (Dang and 
Jayasena, 1996). The single-stranded cDNA template was then subjected to 35 
amplification cycles.   Amplification cycles included the following parameters: 
 Denaturation at 95 oC for 15 seconds. 
 Annealing at the primer-dependent temperature for 15 seconds. 
 Amplicon dependent extension at 72 oC for 25 bp/second. 
The cycle ended by producing a data for quantification analysis which was obtained by 
a single step emitted fluorescence (in channel F1, gain value 3). After the 35th cycle, 
the produced amplicon was prepared for melting curve analysis, thus heated to 95oC 
(denaturation). This was then rapidly cooled to the previous annealing temperature 
(+10oC) for 40 seconds. Up to this stage all heating and cooling steps were performed 
with a slope of 20 oC/s.  
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Further, to obtain data for the melting curve analysis, the temperature was then raised 
to 95oC (melting) with a slope of 0.1 oC/s and the emitted fluorescence was measured 
continuously. The specificity of the amplified PCR product could be assessed via the 
melting curve which differentiates between primer-dimers and the specific product. 
The PCR product was cooled to 40 °C for 30 sec and stored at -20 °C until required. 
Table 2.7: Default conditions for all amplifications for a qRT-PCR 
Analysis 
Mode 
Cycles Segment 
Specific 
Temperature 
(oC) 
Holding  
Time (min) 
- Pre-Incubation - - - 
None 1 - 95 10 
- Amplification - - - 
Quantification 35 Denaturation 95 1 
- - Annealing variable 2 
- - Extension 72 1 
- - - 72 7 
- Cooling - - - 
None 1 - 4 ∞ 
 
2.5.3 Analysis of qRT-PCR product. 
Agarose gel electrophoresis helped to assess the length and purity of the qRT-PCR 
product. Reagents used in the process as mentioned in table 2.8. 
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2.5.4 Agarose gel electrophoresis. 
The 1 x TBE buffer (working solution) was prepared from 10 x TBE (stock solution). 
Agarose gel 2 % (w/v) was prepared in dH2O and heated in a domestic microwave at 
maximum power for 3-4 min until all the crystals dissolved. The solution was cooled to 
70 oC and poured into a gel tray set with a comb. The gel was allowed to set for 30-45 
min. The 1 x TBE buffer (Running buffer), was poured into the gel tank with solidified 
gel in place. Thereafter, the comb was removed carefully. A 10 µl of PCR product was 
mixed with 2 µl of tracking dye and loaded in the wells. A molecular marker of 100bp 
was also loaded with the sample as a reference. The gel was electrophoresed for 3-4 
hours at 70 volts and then stained with 0.5 µg/ml ethidium bromide (EtBr) for 20-30 
min followed by destaining with water for 15-20 min. The banding patterns were 
visualised using a GENE GENIUS Bioimaging system and Genesnap software (Syngene, 
UK). 
Table 2.8: Reagents used for agarose gel electrophoresis. 
Reagents Working concentrations Suppliers 
TBE (10x Ultrapure 10x Tris 
borate EDTA electrophoresis 
buffer) 
1 x = 150 ml of 10x TBE in 1350 ml of dH2O Sigma, UK 
Agarose 2 % (w/v) = 3 g Agarose in 150 ml 1xTBE GIBCO, UK 
Tracking dye 
40 % (w/v) Sucrose , 0.25 % (w/v) 
Bromophenol blue  and 0.25 % (w/v) Xylene 
Gyanole 
Sigma, UK 
Molecular marker (100 bp DNA 
ladder) 
0.5 µg/sample = 1 µl of 500 µg/ml ladder in     
6 µl of tracking dye 
New england 
BioLabs, UK 
Ethidium bromide 
(10 mg/ml) 
0.5 µg/ml = 25 µl EtBr in 500 ml dH2O 
Amresco, 
USA 
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2.5.5 Quantification analysis of qRT-PCR 
The absolute amount of target amplicon was determined by an external standard of 
known concentration or copy number. The quantification of copy numbers from 
crossing point was previously established in our lab using genomic DNA as a template 
(Mohammed, PhD thesis, 2007). A standard curve was plotted from the quantitative 
method established on the Light Cycler® 2.0 Real-Time PCR (Mohammed, PhD thesis, 
2007). A standard  genomic DNA (QIAGEN, UK) with known concentration of 1 µg equal 
to 3.4 x 105 copies of a  single gene, was prepared in five different concentrations 
(0.005, 0.05, 0.5, 5 and 50 ng, refer table 2.9). This was then amplified by the 
LightCycler® using GAPDH reference gene with its threshold cycle (Ct) numbers to 
obtain a standard curve. A standard curve generated was plotted with the crossing 
point or Ct value against copy numbers in order to calculate the copy numbers of the 
unknown samples (CD133, Oct4-A, BMP-2 and GAPDH). 
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A. 
 
B. 
 
Figure 2.8: Standards to calculate the copy number of the targeted gene. A. Light Cycler 
quantification curve generated with known concentration of genomic DNA amplified, showing 
that the higher the concentration of DNA the lower the Ct values i.e. earlier the acquisition of 
fluorescence.  The negative control (Primer alone, NTC) shows no florescence acquisition until 
after 30 Ct (straight line). B. The standard generated from the crossing points showing the 
relationship between Ct values and the copy numbers of the amplified genomic DNA using 
GAPDH as a reference gene (Mohammed, PhD thesis, 2007). 
The equation generated (y = -1.3124Ln(x) + 32.058) from this standard graph was 
rearranged to (=EXP {Ct value-32.058)/-1.3124}) to determine the copy numbers of the 
mRNA expression of all the genes used throughout the study. 
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Table 2.9: Genomic DNA correspondence to its average Ct values and equivalent 
copy number.   
 
 
2.6 Chemosensitivity Assay  
2.6.1 Chemosensitivity 
Glioma cell line U87-MG was subjected to a chemosensitivity assay and was evaluated 
for cell viability. The undifferentiated U87-MG cells (hypoxic and serum-deprived) 
together with the control cells were treated with two drugs Taxol and TMZ for a period 
of 48 hours. An untreated cohort of U87-MG cells served as a negative control without 
the addition of the drugs. The drugs were prepared based on their IC50 values (Table 
2.10) (Lu, 2008). After 48 hours the cells were scraped and their viability was measured 
by means of propidium iodide (PI) staining.     
  Table 2.10: Drug preparation 
Concentration of Genomic 
DNA (ng) 
Average Ct Copy number 
0.005 30.15 1.7 
0.05 29.10 17 
0.5 26.42 170 
5 22.60 1700 
50 18.30 17000 
Drugs 
Molecular 
weights 
Solvents 
Stock 
Concentrations 
(mM) 
Suppliers Cat # 
Taxol (Paclitaxel) 853.91 
Dissolved in methanol, 
subsequently in culture 
medium 
0.3903 Sigma, UK T7402 
Temozolomide 
(TMZ) 
194.15 Culture medium 2.5753 
Schering 
Plough, UK 
25774612 
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2.6.2 Cell Viability  
Previous studies showed cell viability as a quantitative parameter to assess the 
cytotoxicity of drugs in this study (Lu, 2008, PhD Thesis). For this experimental process, 
a non-permeant dye propidium iodide (PI) was used which intercalated into the major 
groove of the DNA of the dead cells. The binding of the dye produced a high 
fluorescent adduct indicating the presence of non-viable cells. 
Cells were scraped and their culture medium was discarded. The cells were then 
washed 3 x with PBS (0.5 ml, 0.1 M) and centrifuged at 1000 rpm for 5 min. An amount 
of 500 µg of PI solution (concentration 10 mg/ml) was added to the cells and incubated 
in the dark for 5 min. The cells were subjected to the viability analysis using the flow 
cytometer. The excitation wavelength for PI is 488 nm whereas its fluorescence is 
detected from 550 nm to 670 nm.  An untreated cell line (no staining) served a 
negative control. For every sample a minimum of 10,000 events/sample was 
considered. All the reagents and samples were kept on ice throughout the 
experimental process. Figure 2.9 demonstrated a typical example of a histogram 
illustrating a cell viability assay performed on the flow cytometer. 
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Figure 2.9: A typical example of a histogram plot of cell viability assay using the flow 
cytometer. Blue histogram represented the population of viable cells and the red histogram 
denoted the population of dead cells stained with PI (Adapted from 
http://www.cdbss.com.cn/?p=2&a=view&r=12). 
 
2.7 Cell cycle analysis 
The cells subjected to undifferentiation and chemotherapeutic drugs were evaluated 
for altered cell cycle phases. Table 2.11 listed the reagents and their 
formulation/concentrations used for cell cycle analysis. The cells (1 x 106 cells) were 
scraped and washed with 1 x PBS (0.5 ml, 0.1M) and then centrifuged at 112 g for 5 
min. The supernatent was discarded and the cells were fixed by resuspending it in 2 ml 
of 70 % ice cold ethanol. Ethanol was added drop wise to the cell pellet to avoid 
clumping of the cells. The cell sample was then stored at -20 oC for a minimum of 24 
hours. The fixed samples were centrifuged at 112 g for 5 min and the supernatant 
consisting mainly of ethanol was discarded and the cells were washed with 1 x PBS (0.5 
ml, 0.1 M). The cells were resuspended in PBS containing PI (50 g/ml) and RNAse (100 
g/ml) and incubated at 37 oC for 30 min. Stained samples were kept at 4 oC in the 
dark until subjected to flow cytometric analysis. 
Total cells  
PI- Viables  
PI + Dead  
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Table 2.11: Reagents used for cell cycle analysis 
Reagents Concentrations Suppliers 
PBS 0.1 M Sigma, UK 
Ethanol 70 % Fisher Scientific, UK 
PI 50 g/ml Sigma, UK 
RNAse 100 g/ml Sigma, UK 
 
 
2.8 Flow cytometry  
Flow cytometry was a previously described technique that helped to measure the 
properties of an individual cell. The cells were labelled with a specific antibody 
conjugated to a fluorochrome and by means of hydrodynamic focusing. Each cell was 
passed through a single or multiple beam of light. The emitted fluorescence (light 
scattering) provided knowledge about the cellular properties. Fluorescence 
measurements taken at different wavelengths provided quantitative and qualitative 
data about fluorochrome-labelled cell surface receptors and/or intracellular molecules 
within a cell (e.g. DNA and cytokines) {Fig. 2.10} 
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Figure 2.10: An illustration of flow cytometry. (Modified from http://www.rudbeck.uu.se                                                      
/showpic.php?id=54). 
 
2.8.1 Sample preparation (adapted from Abcam, UK; modified according to the         
experimental requirement) 
 
Control and treated cells (>1 x 106 cells) were collected by scraping. The cells were 
washed 3 x with bovine serum albumin (BSA) (0.5 ml and 0.1 %) made in PBS (0.5 ml 
and 0.1 M). After each wash the cells were centrifuged at 112 g for 5 min at 4 oC. The 
supernatant was carefully discarded in order to achieve maximum number of cells for 
the analysis. The cells were permeabilised by incubating with 0.1 % of triton-X in               
(100 µl, 0.1 M) PBS for 15 min in the dark, followed by 3 washes with BSA (0.5 ml, 0.1 
%). Blocking solution (made up in 5 % serum in (0.1M) PBS based on the animal in 
which the antibody was raised) was added to the cells and incubated for 30 min at       
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4 oC. After 30 min the cells were centrifuged and the blocking solution was discarded. 
This was followed by the addition of a specific primary antibody (made up in 5 % serum 
with PBS {0.5 ml, 0.1 M}) for 30 min. The primary antibody was removed by 3 x washes 
with BSA (0.5 ml, 0.1 %). Secondary antibody prepared similar the primary antibody 
preparation was added to cell sample and incubated in dark for 30 min.  A number of 3 
x washes with BSA (0.5 ml, 0.1 %) was carried out in order to remove any traces of 
secondary antibody. The cells were finally resuspended in BSA (250 µl, 0.1 %) and then 
filtered to remove clumps using a sterile filter for flow cytometric sample preparation. 
The samples were stored at 4 oC in the dark until analysed on the flow cytometer. The 
negative control was prepared by replacing the labelling with the primary antibody. 
Throughout the experimental process the cell samples and the reagents were kept on 
ice to minimize cell death. The samples during each wash were gently pipetted to 
achieve single cell suspension. 
 
2.8.2 Data analysis 
The cells were gated selectively by eliminating cell debris or dead cells. For each 
sample, a maximum of 10,000 events/samples were taken into consideration. It was 
possible to demonstrate the flow cytometric data by means of a density plot, contour 
diagrams and histograms (Le et al., 2007). Throughout this study histogram graphs 
were used to display relative fluorescence (single parameter) on the x-axis and the 
number of events on the y-axis. Fig. 2.11 represented a histogram plot for flow 
cytometric analysis. A statistical view of the data could be achieved after acquiring 
10,000 events/ sample to identify the exact number of positive cells in a given sample. 
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Figure 2.11: A histogram graph demonstrating flow cytometric data. P1-negative control,       
P2- negative population of cells from sample and P3-positive population of the stained cells. 
(Modified from  http://keck.bioimaging.wisc.edu/Neuro670/Introduction%20to%20Flow%20 
Cytometry.pdf).  
 
Table 2.12: Antibodies used in this study with the dilution factor as recommended by 
the supplier. 
 
 
Proteins Antibodies Types 
Dilution 
Factor 
Suppliers 
CD133 
Primary Rabbit polyclonal IgG 1:100 
Abcam, UK 
Secondary 
Goat polyclonal to Rabbit IgG      
(Cyanine 5-Cy 5) 
1:200 
OCT4-A 
Primary Mouse monoclonal IgG2B 1:50 Santacruz 
biotechnology
, UK Secondary 
Goat anti-mouse  IgG2B                 
(Phyco erythrin-PE) 
1:400 
BMP2 
Primary Mouse monoclonal  IgG 1:100 
Abcam, UK 
Secondary 
Rabbit polyclonal to Mouse  IgG  
(Texas Red-TR) 
1:200 
P1 
P3 
P2 
Negative Control 
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2.9 Immunofluorescence (IF) 
The technique of Immunofluorescence helped to determine the presence and 
localisation of the target protein or antigen in fixed cells or tissue samples.  
Immunofluorescence was carried out by two methods of staining i) Direct staining -  
where the primary antibody was itself conjugated with fluorescent dye and ii) Indirect 
staining - where the primary antibody was detected with the help of a secondary 
antibody conjugated to the fluorescent dye. For this study, the antigen was detected 
using an indirect staining method to localise the proteins of interest with the aid of a 
LSM510 Confocal microscope (fig 2.12). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: Indirect immunofluorescent staining. Primary antibody binds to the antigen on 
the cell and the secondary antibody conjugated to the fluorochrome recognises the primary 
antibody and binds to it. The cells are then visualised under a confocal microscope. (Adapted 
fromhttp://www.biotech.uiuc.edu/images/Indirect_stain_second_image.jpg) 
 
 
Secondary antibody 
Primary antibody 
 
 
 
 
 
 
82 
 
2.9.1 Cell culture IF 
The culture medium was removed from the chamber slides and the cells were washed 
3 x with warm PBS (0.5 ml, 0.1 M) {all the washing steps were carried out for 5 min on 
a shaker}. The cells were then fixed at room temperature with freshly prepared 4 % 
paraformaldehyde (w/v) in PBS (0.5 ml, 0.1 M). The cells were washed 3 x with warm 
PBS (0.5 ml, 0.1 M). After this step, the cells could be stored for a period of 6 months 
at -20 oC for immunofluorescent staining. Permeabilisation was carried out by 
incubating the fixed cell with 0.3 % (v/v) Triton X-100 in PBS (100 µl) at room 
temperature for 7 min. The cells were incubated with a blocking solution with serum 
(based on the species in which the secondary antibody was raised) for 30 min at room 
temperature. The blocking solution minimizes the probabilities of non-specific binding 
within the sample. After the removal of the blocking reagent, the cells were incubated 
with their corresponding primary antibodies (Table 2.12) for 1 hour at room 
temperature. The primary antibody was then removed by washing the cells 3 x with 
warm PBS (0.5 ml, 0.1 M). The cells were then incubated with light sensitive 
fluorochrome (Table 2.12) conjugated secondary antibody (Abcam, UK) diluted in 
blocking solution for further 60 min in a dark room. The secondary antibody was 
removed with three consecutive PBS (0.5 ml, 0.1 M) washes and the cover slips were 
placed on the slides by addition of 1.5 µg/ml VECTASHIELD mounting medium (Sigma, 
UK) and allowed to dry for 10 min. The negative control cells from each sample 
received identical preparations for immunofluorescent staining with no addition of 
primary antibodies. The cells were then visualised and scanned using an Axiovert 200 
LSM 510 laser scanning confocal microscope (Carl Zeiss, UK) (Long et al., 2005)  
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2.10 Proteomics 
Proteomics refers to a large scale study of the characterisation and functions of various 
types of proteins present within a cell, organ, or organism (Adams 2008). Although the 
human genome harbours 26000-31000 protein encoding genes (Baltimore et al., 2001) 
one million proteins have been identified as human protein products, including splice 
variants and proteins essential for post-translational modifications          (Godovac-
Zimmermann and Brown, 2001). Proteomics displayed patterns of hundreds of 
thousands of proteins that were differentially regulated at any time point being 
dynamically modified by different treatments (Whiteley, 2006). Proteomic analysis 
included a combination of complex and sophisticated analytical techniques such as 2D 
Gel electrophoresis for protein separation, image analysis, mass spectrophotometry 
and bioinformatics tools for quantification and characterization of the complex 
proteins (Bensmail and Haoudi, 2003). 
For the present study, proteins were extracted from the U87-MG control and treated 
cells (hypoxia and serum deprivation) and were subsequently quantified. Proteomic 
analysis was performed by Applied Biomics (Hayward, CA). Fig 2.13 illustrated an 
overview of different proteomic strategies and summarised the workflow of 2D-DIGE 
via DeCyder analysis. Highlighted in yellow was the proteomic methodologies used in 
this study. 
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Figure 2.5 An overview of proteomic strategies Methods used in this project are highlighted 
(Adapted from Chandramouli and Quian, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: An overview of proteomic strategies. Methods used in this project are 
highlighted. (Adapted from Chandramouli and Quian, 2009).  
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2.10.1 Protein extraction 
The freshly collected cell pellets were washed 3 x with washing Buffer (10 mM Tris-HCl, 
5 mM magnesium acetate, pH 8.0) to remove any excess culture medium. For 10 mg of 
cultured cell pellet, a volume of 200 µl of 2-D cell lysis buffer (400 mM Tris, 0.01 M 
EDTA; pH 8.3) was added. The mixture was sonicated at 4 °C followed by shaking for 30 
min at room temperature. The samples were then centrifuged at 14,000 rpm for 30 
min. The supernatant was collected. Protein concentration was measured using Bio-
Rad protein assay method. 
 
2.10.2 Protein quantification 
The Bio-Rad Protein Assay is based on the Bradford method previously designed for 
protein quantification. This dye-binding assay produced a differential colour change in 
response to various concentrations of protein (Bradford, 1976). The dye reagent 
concentrate was purchased in a kit with BSA (Biorad, UK) which was used as a 
standard. 
Lyophilized BSA standards were reconstituted by adding 20 ml of deionised water and 
were mixed thoroughly until dissolved. The standard was aliquoted and stored at          
-20 °C for future use. The dye reagent was prepared by diluting 1 part Dye Reagent 
Concentrate with 4 parts of distilled deionized water and this was then filtered through 
Whatman #1 filter. The protein solution was prepared by pipetting 100 µl of each 
standard and sample solution into a clean and dry test tube. Diluted dye reagent (5 ml) 
was added to each tube. The mixtures were vortexed and incubated at room 
temperature for 5 min. The absorbance was measured at 595 nm using gamma thermo 
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Helios spectrophotometer (Thermospectronics, UK). A standard curve was plotted and 
the value of the unknown protein was extrapolated. Each protein assay was repeated 
in triplicate. The protein with additional cell line samples were shipped to the U.S.A on 
dry ice supplemented with ice bags following the instructions recommended by 
Applied Biomics. 
2.10.3 Over view of work carried out by Applied Biomics (U.S.A) (Fig. 2.14) 
a. Two-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE) - This 
technique was used for protein separation under denaturing conditions. The 
principle of separation being that a combination of two orthogonal 
electrophoretic processes {molecular size and isoelectric focusing (IEF)} on a gel 
yields a greater degree of resolution than obtained by a single process         
(Issaq et al., 2002). 
b. Following separation, the gels were stained to visualize separated protein spots 
using various dyes such as colloidal Coomassie brilliant blue G, silver stain and 
fluorescent stain SYPRO Ruby (Gygi et al., 2000).  
c. 2D Fluorescence Difference gel electrophoresis (2D-DIGE) - Samples were 
labelled with one of three spectrally different succinimidyl esters of the 
fluorescent cyanide (Cy) dyes: Cy2, Cy 3 or Cy 5 before the first dimension IEF 
separation. These fluorophores were similar in charge and molecular weight, 
however, they had distinct fluorescent properties which aided their 
discrimination when scanned using appropriate optical filters (Marouga et al., 
2005; Timms and Cramer, 2008; Minden, 2007). In a 2D-DIGE experiment, three 
different samples were covalently labelled, with a different Cy dye. One of the 
sample was a control which could either be an untreated sample or a mixture 
of all samples pooled together, thus, forming a control. The gel was then 
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scanned using a fluorescence imager at specific wavelengths for Cy2                 
(488 nm - control), Cy3 (532 nm – hypoxic) and Cy5 (633 nm – serum-deprived), 
and a gel image for each of the different samples was obtained. The images 
were then merged and analyzed using imaging software to check the 
differential regulation amongst the proteins (Minden, 2007). 
d. DeCyder analysis - this software that contained proprietary algorithms to 
perform co-detection of differently labelled samples within the same gel. 
DeCyder permitted automated detection, background subtraction, 
quantitation, normalization and inter-gel matching and spot picking. This 
resulted in high throughput, minimum introduction of human error and greatly 
increased the reproducibility. Figure 2.14 showed a typical workflow of           
2D-DIGE using DeCyder software.  
e. Mass spectrometry analysis - A mass spectrometer such as Matrix-assisted 
laser desorption/ionization-time of flight (MALDI-TOF) is used primarily for 
protein identification. MALDI measured the mass of peptides derived from a 
trypsinized parent protein and generated a list of experimental peptide masses, 
often referred to as “mass fingerprints” (Vestling and Fenselau, 1994; 
Medzihradszky et al., 2000). The TOF measurement was used as a procedure 
where instead of operating continuously, the pulsed laser took individual shots 
(Duncan and Hunsucker, 2008). 
f. Database search - The peptide masses derived from the mass spectrometer 
analysis correlated with peptide fingerprints of known proteins in a protein 
sequence database using search engines like Sequest, MASCOT, Comet, 
X!tandem, MOWSE , PeptIdent-2 and Profound (Pappin, 1993; Mann, 1993; 
 
 
 
 
 
88 
 
Yates, 1993; Colinge, 2003; Geer, 2004). These search engines provided a list of 
the best matching peptide sequences for an individual tandem mass spectrum. 
In addition, they provided scores that were related to the confidence level in 
the match. In this project MASCOT search engine developed by Matric science 
was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14: Workflow of 2D-DIGE via DeCyder (Adapted from Ettan DIGE User Manual, 2002) 
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2.11 Statistical Analysis 
The experimental data such as PCR, Flowcytometry data, chemosensitivity and              
cell cycle analysis were analyzed by PASW package using One-Sample Student’s T-test 
and paired T-test. A value of *p < 0.05 and **p < 0.001 was considered as significant. 
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Chapter 3 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
 
91 
 
The current investigation primarily deals with changes in the protein expressions of the 
differentiated and undifferentiated brain tumour cells. The three proteins measured in 
this study included CD133, Oct4-A and BMP2. The initial experiments included gene 
expression analysis of the three candidate proteins by means of qRT-PCR. Flow 
cytometry has been extensively used to evaluate the expression of the candidate 
proteins. For analysis, the cells were labelled with the appropriate primary antibodies 
and detected using fluorochrome conjugated secondary antibodies. CD133 protein has 
been detected by an antibody conjugated to Cyanine 5 (Cy-5), Phyco erythrin (PE) used 
to detect Oct-A protein and Phyco erythrin Texas Red (PE-Texas Red) to detect the 
BMP2 protein in the glioma cell lines (Chapter 2; Table 2.4). For the cell viability assay 
and cell cycle analysis, the cells were labelled with PI followed by analysis using a flow 
cytometer. 
 
The results of the present study are presented as follows: 
3.1   Gene expressions of candidate proteins in the control glioma cell lines. 
3.2   Protein expression profiles in the undifferentiated U87-MG cell line. 
3.3   Chemosensitivity assay. 
3.4   Cell cycle analysis. 
3.5   Proteomics. 
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3.1 mRNA, cDNA and qRT-PCR 
mRNA was extracted from the three glioma cell lines namely 1321-N1, Gos-3 and U87-
MG. Spectrophotometry was carried out to evaluate the purity and quantification of 
the isolated mRNA. The mRNA absorbance was measured at wavelengths 260 nm and 
280 nm respectively. Based on the spectrophotometric readings the quantity of mRNA 
required for cDNA conversion was calculated. 
A total of 100 ng of mRNA was reverse-transcribed into c DNA followed by real time 
PCR which helped to measure the expression of the candidate proteins CD133, Oct4-A, 
BMP2 and housekeeping gene GAPDH. Note that there was no significant difference 
observed in the expression of the candidate genes GAPDH, CD133, Oct4-A and BMP2 in 
all the three glioma cell lines 
Figure 3.1: Gene expressions of GAPDH, CD133, OCT4-A and BMP2 in all the three glioma cell 
lines. The respective mean values ± standard error of the copy number of GAPDH, CD133, 
OCT4-A and BMP2 genes expressed in each cell line were included (Data obtained from 3 
independent experiments, n = 3). No statistically significant difference was observed in the 
expressions of the candidate genes when compared between the three different glioma cell 
lines.  
1
10
100
1000
10000
100000
1321-N1 GOS-3 U87-MG 
m
 R
N
A
 c
o
p
y 
n
u
m
b
er
 x
 1
0
3
Glioma cell lines 
GAPDH
CD133
OCT4-A
BMP2
 
 
 
 
 
93 
 
Figure 3.1 showed the expression of the target candidate genes with respect to the 
expression of housekeeping gene GAPDH which was consistently expressed in all the 
three glioma cell lines compared to the other genes. The qRT-PCR results 
demonstrated that expression of CD133 gene was not noticed whereas, BMP2 
expression was only observed more prominently in the U87-MG cells. The expression 
of the pluripotency gene OCT4-A was observed to be marginally elevated in the GOS-3 
cell line as compared to 1321-N1 and U87-MG cells. Statistical analysis using Student’s 
one sample T-test did not show any significance difference in the expression of the 
gene CD133, OCT4-A and BMP2 in the glioma cell lines. 
 
3.2 Expressions of candidate protein levels in the control glioma cell lines 
Figure 3.2 displays the nuclear restricted Oct4-A protein in different grades of glioma 
cell lines. The results show that immunofluorescent staining was negative in the glioma 
cell lines stained with CD133 and BMP2 antibodies. Oct4-A protein was detected 
within the nucleus of all three glioma cell lines 1321-N1, GOS-3 and U87-MG.  
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3.2.1 Oct4-A protein levels in the control glioma cells using IF. 
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                     Figure 3.2: A typical example of nuclear located Oct4-A protein in different grades of glioma 
cell lines. A. phase contrast images of 1321-N1, GOS-3 and U87-MG cell lines. B. Oct4-A 
protein visualised in the nucleus 1321-N1, GOS-3 and U87-MG cell lines. Protein was identified 
using antibodies conjugated to PE. Images were observed using a confocal microscope ( X 40 
magnification, n=3). 
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3.2.2 Candidate protein expressions in the control cells (1321-N1, GOS-3 and U87-MG) using flow cytometry. 
i) Expression profile of CD133, Oct4-A and BMP2 protein in glioma cell line 1321-N1. 
Figure 3.3 illustrates the percentage of positive cells for the candidate proteins. The results show that no CD133 and BMP2 proteins were detected in 
the 1321-N1 cell line using flow cytometric analysis. However, a large number of cells were found to be postive for Oct4-A. Histograms A denotes the 
absence of CD133 protein in the 1321-N1 cell line, B indicates 75 % of the 1321-N1 cell positive with Oct4-A protein whereas, histogram C shows the 
absence of BMP2 protein in the glioma cell line 1321-N1.                   
                          A.                                                                                   B.                                                                                   C. 
              
Figure 3.3: A typical example of expression profiles of CD133, Oct4-A and BMP2 protein in glioma cell line 1321-N1. A. Cells stained with Cy-5 shows no cells 
positive for CD133. B. Gated cell population (blue) represents the cells positive with the Oct4-A protein labelled with PE. C. Cells stained with PE-Texas Red display 
an absence of BMP2 protein. (Data obtained from three independent experiments, n = 3). 
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ii) Expression profile of CD133, Oct4-A and BMP2 protein in glioma cell line GOS-3. 
Figure 3.4 shows the quantitative protein expression profile of CD133, Oct4-A and BMP2 in the GOS-3 cell line. The results indicated that no CD133 
and BMP2 proteins were detected in the GOS-3 cells using flow cytometric analysis. The cell line was found to be positive for a substantial quantity of 
the Oct4-A protein. Absence of CD133 proteinis has been demonstrated by histogram A, histogram B represents approximately 84 % of the GOS-3 
cells positve with Oct4-A protein and histogram C indicates an absence of  the BMP2 protein within the GOS-3 cell line. 
                           A.                                                                                    B.                                                                                 C. 
               
Figure 3.4: A typical quantitative protein expression profiles of CD133, Oct4-A and BMP2 proteins in the GOS-3 cell line. A. Cells stained with Cy-5 shows no cells 
positive for CD133. B. Gated cell population (blue) stained with PE, represents a positive percentage for Oct4-A protein compared with the negative. C. Cells 
stained with PE-Texas Red show an absence of BMP2 protein. (Data obtained from three independent experiments, n = 3) 
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iii) Expression profile of CD133, Oct4-A and BMP2 proteins in glioma cell line U87-MG. 
Figure 3.5 presents the data indicating the percentage of cells positive for CD133, Oct4-A and BMP2 proteins. The results showed that the control     
U87-MG cell line when evaluted for the candidate protein expression showed the presence of only the Oct4-A protein. The expression of CD133 and 
BMP2 proteins were not observed. U87-MG cells did not indicate a presence of CD133 protein represented by histogram A, 72 % of the cells were 
positive for Oct4-A protein and no cells were detected positive for BMP2 protein demonstrated by histogram C. 
                          A.                                                                                   B.                                                                                   C. 
             
Figure 3.5: Percentage of cells positive for CD133, Oct4-A and BMP2 proteins in the U87-MG cells. A. No cells were detected positive for the CD133 protein 
analysed by staining with Cy-5. B. Approximately 73 % of the cells indicated a presence of Oct4-A protein detected by the PE stain. C. U87-MG cells displayed an 
absence of the BMP2 protein. (Data obtained from three independent experiments, n = 3). 
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Table 3.1 shows the quantitative expression of the candidate proteins in different 
grades of glioma cell lines. The control glioma cells were analysed using flow cytometry 
for the presence of proteins CD133, Oct4-A and BMP2. A total event of 10,000 cells 
was considered for each sample. All three cell lines showed a positive expression of 
Oct4-A protein and an absence of CD133 and BMP2 proteins. The highest expression of 
the Oct4-A protein was observed in the GOS-3 cells followed by a similar expression in 
the 1321-N1 and U87-MG cells. However, on carrying out Student’s one sample T-test 
it was found that the number of GOS-3 and U87-MG cells expressing Oct4-A protein 
was statistically significant (*p < 0.05) as compared to the 1321-N1 cell lines. 
Table 3.1: Quantitative expression of CD133, Oct4-A and BMP2 proteins in the 
control glioma cell lines 1321-N1, GOS-3 and U87-MG. Data values are mean ± 
standard deviation (SD), n = 3. *p < 0.05 was considered statistically significant.  
Note that the expression of the candidate proteins was compared between different 
grades of glioma cell lines. There was observed to be a significant increase (p < 0.05) in 
the expression of Oct4-A protein in the GOS-3 and U87-MG cell line compared to   
1321-N1 cells. Expression of CD133 and BMP2 protein was not detected in all the three 
cell lines. 
Cell lines 
 Proteins (Positive percentage {%} )  
CD133 OCT4-A BMP2 
1321-N1 0 75.6 ± 11.8 0 
GOS-3 0 84.3 ± 6.2*  0 
U87-MG 0 72.7 ± 5* 0 
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3.3 Protein expression profiles in the undifferentiated U87-MG cell line. 
Based on the literature search (chapter 1, section 1.7), the U87-MG cell line was found 
to display characteristics similar to CD133, a designated glioma stem cell marker. The 
following results are based on the protein profile evaluated in the U87-MG cells by 
shifting them from a differentiated state to an undifferentiated state. The conditions 
used for the experimental procedure involve two types of micro-environmental 
changes namely Hypoxia and Serum deprivation. The U87-MG cells grown under 
normal cell culture conditions and those subjected to micro-environmental changes 
were observed for morphological changes under the light microscope, followed by a 
qualitative study of the candidate protein expression using immunofluorescence.  
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3.3.1 i) Morphological changes observed in U87-MG cell line subjected to                        
micro-environmental changes.  
Figure 3.6 displays the morphological differences between the differentiated and 
undifferentiated U87-MG cells. The differentiated state was considered to be the 
normal cell culture conditions required for the growth of U87-MG cells. The results 
show that treatment with either hypoxia (100 % nitrogen) for 30 min or serum 
deprivation for a period of 3-7 days induced a state similar to undifferentiation within 
the cells.  
A.  
 
  
 
 
                  
 
  
 
    B. C.  
                                  
Figure 3.6: A typical example of morphological changes induced in U87-MG cells due to 
micro-environmental changes.  A. Control U87-MG cell line grown in EMEM media. B. U87-MG 
cells observed after 24 hrs of treatment with hypoxia for 30 min. C. Serum-deprived U87-MG 
cell transformed into neurospheres when grown in RHB-A media supplemented with hEGF and 
bFGF to enhance their undifferentiation. Cells were observed under a light microscope 
(magnification x 20, n=3). 
Undifferentiated state 
Hypoxia  Serum deprivation  
Differentiated state 
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ii) Qualitative protein expressions by immunofluorescent staining.  
Cells were studied for the presence of candidate proteins using immunofluorescence. 
The results demonstrated in figure 3.7 display the peripheral localisation of the CD133 
protein in the hypoxia-treated U87-MG cells. The presence of Oct4-A was visualised in 
the nucleus of the U87-MG cells in a state of differentiation and undifferentiation. The 
BMP2 protein was not detected in the U87-MG cells. 
                                                        A                                                       B 
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       Figure 3.7: A typical example displaying CD133 and Oct4-A proteins in the hypoxic U87-MG 
cells. A, C. phase contrast images of hypoxia-treated U87-MG cell line. B. Cell surface 
localisation of CD133 on the hypoxic U87-MG cells detected by Cy-5 staining. D. Nuclear 
location of Oct4-A protein in the U87-MG cell line identified using antibody conjugated to PE. 
Image observed confocal microscope (X 40 magnification, n=3). 
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3.3.2 Analysis of CD133, Oct4-A and BMP2 protein expressions in the U87-MG control cells. 
Figure 3.8 displays the measurement of the protein expression profiles in the control U87-MG cells. Under normal cell culture conditions 
(differentiated state) the U87-MG cells did not display presence of CD133 and BMP2 protein as demonstrated in histograms A and C, respectively. 
Approximately 65 % of U87-MG cells were noticed to be positive for Oct4-A protein as represented by histogram B. 
                       A.                                                                                     B.                                                                                    C. 
              
Figure 3.8: Percentage of cells positive for CD133, Oct4-A and BMP2 proteins in the U87-MG control cells. A. No cells were detected positive for CD133 protein, 
stained using Cy-5. B. Blue histogram indicate cells positive for the Oct4-A protein detected by staining the cells with PE. C. U87-MG cells display an absence of the 
BMP2 protein. (Data obtained from three independent experiments, n = 3). 
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3.3.3 Analysis of CD133, Oct4-A and BMP2 protein expressions in U87-MG cells treated 30 min with hypoxia (followed by 24 hr incubation).  
Figure 3.9 displays the protein expression profiles in the hypoxia-treated U87-MG cells.  Flow cytometric analysis of hypoxia-treated cells showed a 
basal expression (2 %) of CD133 protein in U87-MG cells as observed in histogram A. The expression of the Oct4-A protein was found to be 
significantly increased (p < 0.05, 84 %) as compared to the control U87-MG cells demonstrated in histogram B. Histogram C indicates that the 
presence of the BMP2 protein was not observed in the hypoxic U87-MG cell line. 
   A.                                                                                    B.                                                                                     C. 
                  
Figure 3.9: Analysis of the protein expression profile followed by hypoxia treatment. A. Red coloured histogram displays a minimal expression of the CD133 
protein expression observed on account of hypoxia. Cells detected through fluorophore Cy-5. B. Cells positive for Oct4-A, stained with PE represented by the blue 
colour gated histogram. C. No cells observed to be positive for the presence of the BMP2 protein, perceived using PE-Texas Red. (Data obtained from three 
independent experiments, n = 3). 
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3.3.4 Analysis of CD133, Oct4-A and BMP2 protein expressions in U87-MG cells after serum deprivation (5 days). 
Figure 3.10 displays the protein expression profiles in the serum-deprived U87-MG cells. Histogram A indicates that the serum-deprived U87-MG 
cells did not display presence of CD133 protein. Similarly, an absence of BMP2 was observed in the U87-MG cells under serum-deprived conditions, 
displayed in histogram C. Histogram B shows that serum deprivation for a period of 5 days led to a decrease in the expression of Oct4-A protein      
(43 %) as compared to the control U87-MG cell.  
                            A.                                                                                    B.                                                                                    C. 
                 
Figure 3.10: Proteins detected in serum-deprived U87-MG cells. A. Histogram indicates the absence of CD133 protein following serum deprivation. B. A marginal 
expression of the Oct4-A protein in the U87-MG cells detected using PE fluorochrome. C. No cells display positive for protein BMP2 stained with PE-Texas Red. 
(Data obtained from three independent experiments, n = 3). 
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U87-MG cells were studied for changes in the candidate protein expression when 
shifted from the differentiated state to an undifferentiated state. An attempt to shift 
the cells towards the undifferentiated state was carried out by induction of                   
micro-environmental changes such as hypoxia and serum deprivation. Table 3.2 enlists 
the number of cells positive for the expression of candidate proteins as a result of            
micro-environmental changes. 
Table 3.2: Quantitative expression of proteins CD133, Oct4-A and BMP2 in the        
U87-MG glioma cell line when subjected to treatment of hypoxia and serum 
deprivation compared to the untreated cells. Data values are mean ± standard 
deviation (SD), n = 3. *p < 0.05 was considered statistically significant.  
Note that there was no significant difference observed in the expression of CD133 and 
BMP2 proteins in the treated U87-MG cells. the expression was Oct4-A protein 
changed significantly in the hypoxic and serum-deprived cells as compared to the 
control U87-MG cells. 
 
While no expression of BMP2 was observed in the U87-MG cells, the percentage of 
Oct4-A protein expression increased by 14.1 % in the hypoxia-treated cells and 
decreased by 26.7 % in serum-deprived cells compared to the control. A basal 
expression of the CD133 protein (2.3 %) was observed only in the cells treated with 
hypoxia. Statistical analysis proved a significance difference in the expression of Oct4 
protein (*p < 0.05) when the cells were subjected to hypoxia and serum deprivation as 
compared to the control U87-MG cells. 
U87-MG 
Proteins (Positive %)  
CD133 OCT4-A BMP2 
Control 0 69.9 ± 11.4 0 
Hypoxia   2.3 ± 2 84 ± 7.7* 0 
Serum deprivation  0 43.2 ± 4.9* 0 
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3.4 Chemosensitivity and Cell viability using Taxol and TMZ 
Differentiated and undifferentiated U87-MG cells were tested for the toxicity of 
chemotherapeutic drugs Taxol and TMZ. The experiments were performed by treating 
the control, hypoxic and serum-deprived cells with the drugs and then subjected to the 
cell viability assay. The analysis was carried out by staining the cells with PI which 
displayed the number of dead cells using the flow cytometer. U87-MG cells grown 
under normal cell culture conditions served as a reference for the cell viability assay   
(PI staining) and U87-MG cells grown under normal cell culture conditions with the 
respective drug treatment served as a control for the chemosensitivity assay.  
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3.4.1 Cell viability assay for the U87-MG cells treated with Taxol. 
Figure 3.11 demonstrates the cytotoxic effect of Taxol on the control, hypoxic and serum-deprived U87-MG cells. The flow cytometric histograms 
display the percentage of dead cells indicating the toxicity of Taxol on the U87-MG cells. Histogram A represents the untreated cells displaying 
maximum number of live cells when stained with PI. Control and hypoxic cells displayed an identical number of dead cells (9 %) when treated with 
taxol are demonstrated in histogram B and C, respectively. Histogram D displayed 36 % of dead cells when treated with taxol under serum-deprived 
conditions.  
           A.                                                                     B.                                                                     C.                                                                    D. 
          
Figure 3.11: Cell viability assay results of U87-MG cells treated with Taxol. A. Control U87-MG cells without drug treatment. B. Control U87-MG cells treated with 
Taxol. C. Hypoxic U87-MG cells treated with Taxol. D. Serum starved U87-MG cells when treated with Taxol. Cells stained with PI indicate the percentage of dead 
cells (gated population) on treatment with Taxol. (Data obtained from three independent experiments, n = 3). 
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3.4.2 Cell viability assay for the U87-MG cells treated with TMZ. 
Figure 3.12 displays the cytotoxic effect of the drug TMZ on the control, hypoxic and serum starved U87-MG cells. The results show the percentage of 
dead U87-MG cells when treated with TMZ.  Histogram A represents maximum number of live U87-MG cells when treated with TMZ. Histogram B 
shows approximately 6 % of control dead U87-MG cells on TMZ treatment. Histogram C shows a minimum of 3 % cell dead percentage in the hypoxic 
U87-MG cells when treated with TMZ. Serum-deprived U87-MG cells displayed 26 % of dead cell when subjected to TMZ as displayed in histogram D. 
A.                                                                 B.                                                               C.                                                                   D. 
      
Figure 3.12: Percentage of dead U87-MG cells on treatment with TMZ following cell viability count. A. Control U87-MG cells without drug treatment. B. Control 
U87-MG cells treated with TMZ. C. Hypoxic U87-MG cells treated with TMZ. D. Serum starved U87-MG cells when treated with TMZ. Cells stained with PI indicate 
the percentage of dead cells (gated population) on treatment with TMZ. (Data obtained from three independent experiments, n = 3).
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The results show that the percentage of dead cells with Taxol remained identical for 
both the control and hypoxic U87-MG cells. Serum-deprived cells responded to Taxol 
treatment with a 36.5 % cell death. Similar effects were observed when the cells were 
treated with TMZ; however, serum-deprived cells indicated a 26 % cell death. The 
cytotoxic effect of Taxol was found to be enhanced by 3 % in the control and hypoxic 
U87-MG cells, whereas the toxicity increased by approximately 10 % in serum-
deprived U87-MG cells.  Table 3.3 demonstrates the percentage of dead cells when 
subjected to individual treatment with Taxol and TMZ. 
Table 3.3: Cell viability results of the chemosensitivity assay using flow cytometry. 
Data values are mean ± standard deviation, n = 3. *p < 0.05 was considered to be 
statistically significant for serum-deprived U87-MG cells when as compared to the 
control. 
 
 
 
 
 
 
 
Statistical analysis using Student’s paired T-test indicated that there were no 
significant difference observed in the action of the chemotherapeutic drugs Taxol and 
TMZ on the U87-MG cells. However, individual data set comparison showed that the 
serum-deprived U87-MG cells had a significant dead cell percentage (*p < 0.05) as 
compared to the control cells treated individually with Taxol and TMZ respectively.
  
Chemotherapeutic 
Drugs 
Percentage of dead cells (%) 
Control Hypoxic  
Serum-
deprived  
Taxol  9.3 ± 1.5 9 ± 2.7 36.5 ± 6.2*  
TMZ  5.9 ± 4.7 3.1 ± 0.8 26.1 ± 0.4* 
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3.5 Cell cycle analysis 
In addition, the U87-MG cells were subjected to cell cycle analysis under conditions of 
differentiation (control) and undifferentiation (hypoxia and serum deprivation). Cell 
cycle analysis was further performed on the differentiated and undifferentiated       
U87-MG cells treated with either Taxol or TMZ. With the experiments carried out, the 
control, hypoxic and serum-deprived U87-MG cells were analysed with the treated 
samples to serve as a reference. The results have been demonstrated in the form of 
histograms in fig. 3.13, 3.14 and 3.15, respectively, indicating different cell cycles 
phases. The gated population in P2 represents the cells in G1 phase, the gated 
population P3 (depression) indicates the percentage of cells in the S phase and the P4 
gated population denotes the G2 phase of the cells.  
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3.5.1 Cell cycle analysis of the control, hypoxic and serum-deprived U87-MG cells. 
Figure 3.13 demonstrates the different cell cycle phases of the control, hypoxic and serum-deprived U87-MG cells. U87-MG cells were subjected 
to cell cycle analysis under differentiated (control) and undifferentiated (hypoxia and serum deprivation) states. Histogram A represents the cell 
cycle phase of the control U87-MG cells (G1 - 72.3 %, S - 12.3 % and G2 – 14.5 %). Histogram B denotes the cell cycle phase of hypoxia-treated      
U87-MG cells (G1 – 68.5 %, S – 15.1 % and G2 – 15.5 %) and histogram C represents the cell cycle phase of serum-deprived U87-MG cells              
(G1 – 64.8 %, S – 19 % and G2 – 20.4 %). 
                     A.                                                                                    B.                                                                                   C. 
               
Figure 3.13: A typical example of cell cycle analysis of control, hypoxic and serum-deprived U87-MG cells. A. Control, B. Hypoxic and C. Serum-deprived.    
Gate P2 represents G1 phase, P3 (depression) indicates the S phase and P4 denotes the G2 phase of the cells. (Data obtained from three independent 
experiments, n = 3). 
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3.5.2 Cell cycle analysis of the U87-MG cells treated with Taxol. 
Figure 3.14 represents cell cycle phases of U87-MG cells treated with Taxol. Control, hypoxic and serum-deprived U87-MG cells were subjected to 
treatment with Taxol and were further analysed for changes in their cell cycle phases. Histogram A represents the cell cycle phase of the control 
U87-MG cells treated with taxol (G1 – 33.7 %, S – 18.7 % and G2 – 46.4 %). Histogram B denotes the cell cycle phase of hypoxic U87-MG cells  
treated with taxol (G1 – 27.1 %, S – 14.6 % and G2 – 56.1 %) and histogram C represents the cell cycle phase of serum-deprived U87-MG cells              
(G1 – 58.6 %, S – 14.6 % and G2 – 25.8 %) when subjected to taxol treatment. 
                      A.                                                                                   B.                                                                                 C. 
            
Figure 3.14: A typical example of cell cycle analysis of U87-MG cells treated with Taxol. A. Control cells treated with Taxol, B. Hypoxic cells treated with Taxol. 
C. Serum-deprived cells treated with Taxol. Gate P2 represents G1 phase, P3 (depression) indicates the S phase and P4 denotes the G2 phase of the cells. (Data 
obtained from three independent experiments, n = 3). 
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3.5.3 Cell cycle analysis of U87-MG cells treated with TMZ. 
Figure 3.15 represents cell cycle phases of U87-MG cells treated with TMZ. Control, hypoxic and serum-deprived U87-MG cells were treated with 
TMZ and analysed for changes in their cell cycle phases. Histogram A represents the cell cycle phase of the control U87-MG cells treated with TMZ 
(G1 – 44.8 %, S – 23.7 % and G2 – 30.4 %). Histogram B denotes the cell cycle phase of hypoxic U87-MG cells  treated with TMZ (G1 – 47.2 %, S – 
28 % and G2 – 23.7 %) and histogram C represents the cell cycle phase of serum-deprived U87-MG cells  (G1 – 59 %, S – 13.4 % and G2 – 25.9 %) 
when subjected to TMZ treatment. 
                            A.                                                                                   B.                                                                                  C. 
              
Figure 3.15: A typical example of cell cycle analysis of U87-MG cells treated with TMZ. A. Control, B. Hypoxic cells treated with TMZ and C. Serum-deprived 
cells treated with TMZ. Gate P2 represents G1 phase, P3 (depression) indicates the S phase and P4 denotes the G2 phase of the cells. (Data obtained from three 
independent experiments, n = 3). 
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The control, hypoxic and serum-deprived cells were subjected to cell cycle analysis 
before and after the treatment with Taxol and TMZ. Flow cytometric data displayed a 
differential percentage of cells residing in the G1, S and G2 phase, respectively. Table 
3.4 shows the percentage of the U87-MG cells in various phases of cell cycle on 
account of the drug treatment and their state of differentiation. 
Table 3.4: Percentages of differentiated and undifferentiated U87-MG cells in                       
diverse phases of cell cycle and on treatment with cytotoxic drugs Taxol and TMZ as 
compared to the control. Data values are mean ± standard deviation, n = 3. *p < 0.05 
and **p < 0.001 were considered statistically significant for phases G1, S and G2. 
 
U87-MG cells  
Cell Cycle Phases  (Percentage {%} of cells in the 
phase) 
G1 S G2  
Control  72.3 ± 0.3 12.3 ± 1.6 14.5 ± 1.6 
Hypoxic  68.5 ± 1.4* 15.1 ± 2.6 15.5 ± 2.2 
Serum-deprived 64.8 ± 3.1* 19.0 ± 6.6** 20.4 ± 3* 
    
Control (Taxol) 33.7 ± 2.3 18.7 ± 2.9 46.4 ± 1.6 
Hypoxic (Taxol) 27.1 ± 0.9* 14.6 ± 5.3 56.1 ± 5.8 
Serum-deprived 
(Taxol) 
58.6 ± 3.7* 14.6 ± 0.2* 25.8 ± 4.1* 
    
Control (TMZ) 44.8 ± 5.9 23.7 ± 4.1 30.4 ± 10.2 
Hypoxic (TMZ) 47.2 ± 2.4 28 ± 2.8 23.7 ± 5.2 
Serum-deprived 
(TMZ) 
59 ± 5.5* 13.4 ± 1.8** 25.9 ± 3.4 
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Figure 3.16 shows a graphical view of the control, hypoxic and serum-deprived cell 
proportion residing in different cell cycle phases. The results indicate that the cell cycle 
analysis of the control, hypoxic and serum-deprived cells did not show any significant 
changes in the cell cycle phases.  
 
Figure 3.16: A typical example of cell cycle phases of control, hypoxic and serum-deprived 
U87-MG cells. G1 and G2 represent the gap phase and S denotes the phases of DNA synthesis. 
(Data values are mean ± standard deviation (SD)  from three independent experiments, n = 
3). *p < 0.05 and **p < 0.001 were considered statistically significant as compared to the 
control. 
Student’s paired T-test was performed for the different cell cycle phases of the control, 
hypoxic and serum-deprived U87-MG cells. It was observed that the G1 phases of the 
hypoxic and serum-deprived U87-MG cells was significantly different (* p < 0.05) as 
compared to the control cells. The S phase of the hypoxic cells was similar to the 
control, however, the serum-deprived cells showed a significant number of cells (** p 
< 0.001) residing in the respective phase. * p < 0.05 in the G2 phases of the serum-
deprived cells indicated a statistical significance as compared to the control U87-MG 
cells. 
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Figure 3.17 represents the different cell cycle phases of the control, hypoxic and 
serum-deprived U87-MG cells treated with Taxol. The results display a similarity in the 
G1, S and G2 phases of the control and hypoxic U87-MG cells. The S phase of the 
serum -deprived cells was similar to that of the control and hypoxic U87-MG cells. An 
increase the G1 phase was observed in the serum-deprived cells (58.6 %), whereas, the 
percent of cells dropped significantly in the G2 phase (25.8 %).  
 
Figure 3.17: A typical example of cell cycle phases of control, hypoxic and serum-deprived 
U87-MG cells treated with Taxol. G1 and G2 represent the gap phase and S denotes the 
phases of DNA synthesis. (Data values are mean ± standard deviation (SD)  from three 
independent experiments, n = 3). *p < 0.05 was considered statistically significant for the 
hypoxic and serum-deprived cells as compared to the control U87-MG cell. 
A significant difference (* p < 0.05) was observed it the G1 phase of the hypoxic and 
serum-deprived U87-MG cells on Taxol treatment. A similar difference (* p < 0.05) was 
observed in the S and G2 phases of the serum-deprived cells when subjected to taxol 
treatment. However, no changes were observed in the S and G2 phases of the hypoxic 
U87-MG cells as compared to the control when treated with Taxol. 
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Figure 3.18 demonstrates the percentage of TMZ-treated control, hypoxic and serum-
deprived U87-MG cells in various cell cycle phases. The results show that the cell cycle 
phases of serum-deprived U87-MG cells treated with TMZ indicated a high number of 
cells residing in the G1 phase (59 %) as compared to the control and the hypoxic cells. 
A decrease in the number of serum-deprived U87-MG cells was found in the S phase of 
the cell cycle. No difference was observed in the cell cycle phases of the control and 
hypoxic U87-MG cells.  
 
Figure 3.18: A typical example of cell cycle phases of control, hypoxic and serum-deprived 
U87-MG cells treated with TMZ. G1 and G2 represent the gap phase and S denotes the phases 
of DNA synthesis. (Data values are mean ± standard deviation (SD) from three independent 
experiments, n = 3). *p < 0.05 and **p < 0.001 were considered statistically significant. 
The results from Student’s paired T-test showed that the G1 phase of the serum-
deprived TMZ treated cells was significantly higher (* p < 0.05) as compared to the 
control TMZ treated cells. A higher significant difference (** p < 0.001) was observed in 
the S phase of the serum-deprived cells as compared to the control cells when 
subjected to TMZ. No statistical difference was observed in the G2 phases of the 
control, hypoxic and serum-deprived U87-MG cells on TMZ treatment.
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3.6 Proteomic analysis 
Proteomic analysis enabled monitoring the changes in the protein expression profile of 
the differentiated and undifferentiated U87-MG cells. The proteomic analysis was 
carried out by Applied Biomics (Hayward, CA). A complete study was carried out on the 
U87-MG (control/differentiated) cells, U87-MG hypoxic (undifferentiated) and          
U87-MG serum-deprived (undifferentiated) cells using the 2D-DIGE and MALDI-TOF.    
A total of 96 spots of proteins were identified by the 2D-DIGE analysis using the cut-off 
of fold ≥ 2. The spots were selected using the De-Cyder analysis software and 
confirmed visually. The proteins identified can be observed as circled spots with an 
estimated grid of molecular weight (MW) and isoelectric points (pI) (Fig. 3.19). 
Mass spectrophotometric analysis was performed using MALDI-TOF. For protein 
identification a total of 44 spots were chosen. Protein identification was based on 
peptide fingerprint mass mapping (using MS data) and peptide fragmentation mapping 
(using MS/MS data). MASCOT search engine was used to identify proteins from 
primary sequence databases, 37 of 44 spots were confidently identified as human 
proteins. “Protein ID” numbers correspond to the assigned numbers on the overlay gel 
images and are summarized in Table 3.5. Protein analysis identified more than one 
spots as the same protein. The reason could be attributed to the presence of different 
isoforms of the same protein due to post-translational modifications such as 
phosphorylation, methylation, degradation or cross-linkage within the proteins that 
alter the protein's MW and/or pI, causing the spots to shift. Publically available 
database Human protein research database (HPRD) was used to analyse the biological 
significance of the 44 identified proteins summarized in Table 3.6. 
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A. U87-MG Control and U87-MG-Hypoxic.                                                               B. U87-MG Control and U87-MG-Serum-deprived.  
 
             
Figure 3.19: Representation of a typical 2D-DIGE protein expression profiles. A. U87-MG hypoxia-treated gel sample superimposed on the control. B. U87-MG 
serum-deprived gel sample overlaid on the control. Proteins observed as circled spots with an estimated grid of MW and pI. The red and green spots represent the 
up and down-regulated proteins, respectively. (Gel image demonstrates a single experiment performed on the U87-MG cells, n=1 due to cost).                                            
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Figure 3.19 represents the gel images obtained after performing 2D-DIGE experiment 
for protein expression profile. Figure 3.18(A) displays the image of U87-MG hypoxia- 
treated gel sample superimposed on the control and figure 3.18 (B) represents the 
U87-MG serum-deprived gel sample overlaid on the control. The scale overlaid on the 
gel images represents the protein pI and MW grid which aids in the identification of 
the proteins. The circled numbered spots represent a total of 96 spots suggested for 
protein identification by the Decyder analysis software. Red spots visualised on the gel 
images denoted the upregulated protein and the green dots indicate the proteins that 
has been down-regulated on account of hypoxia and serum deprivation, respectively. 
3.6.1 Differential protein expression profiles obtained using Mass 
spectrophotometric analysis 
A total number of 44 identified peptides were searched against the Mascot database. 
Proteins were categorized as up-regulated, down-regulated or differentially regulated 
based on induction of hypoxic and serum deprivation (micro-environmental changes 
/undifferentiated state) with reference to the U87-MG cells (control/ differentiated 
state) grown under normal cell culture conditions. The results shown in table 3.5 
summarises the protein names, NCBI GI numbers, protein molecular weights, ion 
charges, peptide counts, protein scores,  protein scores C. I. %, total ion scores and 
total ion C.I. % scores as generated by MASCOT. The fold change values of the 
individual protein expressions were measured as U87-MG-control v/s the U87-MG-
hypoxic and U87-MG-control v/s the U87-MG-serum-deprived and are enlisted in the 
last two column of Table 3.5. The molecular class, molecular function and biological 
function of the proteins identified by mass spectrophotometry using Human Protein 
Research Database have been enlisted in Table 3.6. 
 
 
  
 
 
 
 
   
121 
 
 
 
 
Table 3.5:  Differential protein expression profiles. (Data obtained from a single mass spectrophotometric analysis, n=1). 
The selected peptides with ≥ 2 fold change were searched against MASCOT database for the corresponding proteins. Proteins were categorized 
according to their change in expression post treatment with hypoxia and serum deprivation U87-MG glioma cell line.  
Top Ranked Protein Names Accession No. 
 
Protein 
MW 
 
Protein 
PI 
 
Peptide 
Counts 
 
Protein 
Scores 
 
Protein 
Scores 
C. I. % 
 
Total 
Ion 
Scores 
 
Total 
Ions    
C. I. % 
U87-MG 
hypoxic /  
U87-MG 
U87-MG  
Serum-
deprived/
U87-MG 
A. Up-regulated proteins           
Alpha 2 type VI collagen isoform 2C2 precursor gi|115527062 108511.9 5.9 20 423 100 296 100 1.3 3.3 
Heat shock protein 90kDa beta (Grp94)  gi|119618129 40939.0 4.4 9 384 100 327 100 1.0 4.1 
Laminin A/C isoform 2   gi|5031875 65095.6 6.4 17 310 100 205 100 1.2 4.7 
Laminin-binding protein   gi|34234 31773.9 4.8 10 582 100 504 100 2.0 11.8 
Unnamed protein product   gi|158257566 45310.3 5.5 11 200 100 120 100 1.2 4.9 
Vimentin   gi|5030431 41537.0 4.8 22 299 100 108 100 1.2 4.2 
CLN2   gi|37182127 60420.1 5.9 5 228 100 210 100 1.0 3.5 
Fructose-biphosphate aldolase A gi|4557305 39395.3 8.3 17 519 100 348 100 1.8 3.9 
Selenophosphate synthetase 1   gi|24797148 42882.7 5.6 11 203 100 125 100 1.3 3.4 
Alpha-tubulin  gi|37492 50125.6 5.0 10 364 100 303 100 1.6 3.7 
PGK1   gi|48145549 44574.1 8.3 16 532 100 368 100 1.0 7.5 
Poly(rC) binding protein 3 isoform 1   gi|194306631 39440.3 8.2 2 238 100 233 100 1.4 3.6 
Protein phosphatase 2, beta isoform   gi|4758952 35552.3 5.2 12 226 100 138 100 1.1 5.5 
Coenzyme Q9 homolog  gi|40789233 35486.6 5.6 8 120 100 64 100 1.0 3.1 
Capping protein (actin filament) muscle Z-line, beta,  gi|119615295 29998.2 5.9 11 219 100 138 100 1.0 3.0 
Chain A, Fidarestat bound to human aldose reductase  gi|13096112 35699.4 6.6 13 515 100 331 100 1.1 3.8 
Glyceraldehyde-3-phosphate dehydrogenase gi|7669492 36030.4 8.6 9 337 100 244 100 1.2 12.3 
Uracil DNA glycosylase gi|35053 35470.1 8.2 12 348 100 245 100 1.2 6.5 
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Table 3.5 (Contd). 
 
Top Ranked Protein Names Accession No. 
 
Proteins 
MW 
 
Proteins 
PI 
 
Peptide 
Counts 
 
Protein 
Scores 
 
Protein 
Scores 
C. I. % 
 
Total 
Ion 
Scores 
 
Total 
Ion    
C. I. % 
U87-MG 
hypoxic /  
U87-MG 
U87-MG  
Serum-
deprived/
U87-MG 
A. Up-regulated proteins           
Eukaryotic translation initiation factor 4E isoform 2 gi|194578909 28759.6 6.0 5 116 100 96 100 2.6 2.2 
Triosephosphate isomerase 1 gi|17389815 26624.7 6.5 11 308 100 219 100 1.2 4.9 
Phosphoglycerate mutase 1 (brain) gi|4505753 28785.8 6.7 9 176 100 113 100 1.1 3.1 
Phosphoglycerate mutase 1 (brain) gi|38566176 28801.9 6.7 12 305 100 183 100 1.2 6.5 
Similar to Chain , Heat-Shock Cognate 70kd Protein gi|51095055 25582.3 7.0 3 128 100 116 100 1.1 4.3 
H3L-like histone gi|37654352 12096.7 10.6 3 85 100 70 100 1.4 7.3 
B. Down-regulated proteins           
Heat shock protein 90kDa beta, member 1   gi|4507677  92411.3 4.8 22 826 100 614 100 -1.2 -2.7 
ATP citrate lyase isoform 1   gi|38569421  120761.9 7.0 29 481 100 276 100 -1.0 -2.4 
Moesin   gi|4505257  67777.8 6.1 31 700 100 428 100 -1.0 -2.9 
Glutamine-fructose-6-phosphate transaminase 2   gi|12652545  76867.7 7.0 20 205 100 96 100 -1.3 -2.6 
Phenylalanyl-tRNA synthetase, alpha subunit   gi|4758340  57527.5 7.3 12 181 100 113 100 -1.0 -2.8 
C. Differentially regulated proteins           
Transformation upregulated nuclear protein gi|460789 51040.4 5.1 10 164 100 98 100 -1.2 3.9 
Nicotinamide phosphoribosyltransferase precursor  gi|5031977  55486.6 6.7 20 410 100 258 100 -1.2 3.4 
Vimentin variant 3   gi|167887751  49623.1 5.2 28 876 100 581 100 -1.0 6.3 
Casein kinase II alpha 1 subunit isoform a   gi|4503095  45114.8 7.3 12 185 100 111 100 -1.1 5.3 
SEC13-like 1 (S. cerevisiae), isoform CRA_b   gi|119584482  37521.1 5.3 10 284 100 221 100 -1.1 4.7 
Tubulin, beta 2C   gi|23958133  49808.0 4.8 11 225 100 152 100 -1.1 5.1 
 
 
  
 
 
 
 
   
123 
 
 
 
 
 
Table 3.5 (Contd). 
 
 
 
 
 
Top Ranked Protein Names Accession No. 
 
Proteins 
MW 
 
Proteins 
PI 
 
Peptide 
Counts 
 
Protein 
Scores 
 
Protein 
Scores 
C. I. % 
 
Total 
Ion 
Scores 
 
Total 
Ion     
C. I. % 
U87-MG 
hypoxic /  
U87-MG 
U87-MG  
Serum-
deprived/
U87-MG 
A. Differentially regulated proteins           
Chain A, crystal structure of human peroxisomal   gi|183448176  32718.4     6.4 8 197 100 124 100 -1.1 3.8 
Glyceraldehyde-3-phosphate dehydrogenase   gi|31645  36031.4     8.3 11 341 100 236 100 -1.0 10.3 
Glyceraldehyde-3-phosphate dehydrogenase  gi|7669492  36030.4     8.6 12 340 100 252 100 -1.1 6.7 
Annexin A2, isoform CRA_c   gi|119597993  32428.6     5.9 17 481 100 318 100 -1.1 3.1 
Cathepsin B  gi|741376  17143.0     5.4 6 272 100 217 100 -1.0 3.5 
Chain A, Human Aldose Reductase Mutant L301m   gi|171848769  35848.4     6.5 12 138 100 54 100 -1.0 3.6 
Manganese-containing superoxide dismutase  gi|30841309  23658.0     6.9 10 353 100 251 100 -1.4 4.2 
Chain A, structural and kinetic study of the differences 
between human and E.coli manganese superoxide 
dismutase  
gi|194708956  21858.0     6.4 12 397 100 248 100 -1.3 5.3 
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Table 3.6: Molecular class, molecular function and biological function of proteins identified by mass spectrophotometry using Human Protein 
Research Database (HPRD). (Data obtained by single HPRD analysis, n=1). 
The 44 identified proteins were further subjected to human protein research database to describe the details of their molecular classes, molecular 
and biological functions. 
Proteins Molecular classes  Molecular Functions  Biological functions 
A. Up-regulated proteins    
Alpha 2 type VI collagen isoform 2C2 precursor Matrix protein Extracellular matrix structural 
constituent 
Cell growth and/or maintenance 
 
Heat shock protein 90kDa beta (Grp94),   Chaperone Chaperone activity Cell communication; signal transduction 
Laminin A/C isoform 2   Structural protein Structural molecule activity Cell growth and/or maintenance, strongly expressed in malignant gliomas 
Laminin-binding protein   Transcription 
regulatory protein 
Transcription regulator activity Regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolism, Stem & glial cell differentiation. 
Unnamed protein product   Heat shock protein Heat shock protein activity Protein metabolism 
Vimentin   Cytoskeletal protein Cell communication ; Signal 
transduction 
Cell growth and/or maintenance 
CLN2   Enzyme: Hydrolase Metabolism ; Energy pathways Metabolism ; Energy pathways 
Fructose-biphosphate aldolase A Enzyme: Lyase Lyase activity Metabolism ; Energy pathways 
 
Selenophosphate synthetase 1   Enzyme: Synthase ATP binding Metabolism ; Energy pathways 
Alpha-tubulin  Cytoskeletal protein Structural constituent of 
cytoskeleton 
Cell growth and/or maintenance 
PGK1   Enzyme: 
Phosphotransferase 
Catalytic activity Metabolism ; Energy pathways 
Poly(rC) binding protein 3 isoform 1   RNA binding protein RNA binding Regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolism 
Protein phosphatase 2,  beta isoform   Serine/threonine 
phosphatase 
Protein serine/threonine 
phosphatase activity 
Cell communication ; Signal transduction 
Coenzyme Q9 homolog  Unclassified Molecular function unknown Biological process unknown 
Capping protein muscle Z-line, beta. Structural protein 
 
Structural molecule activity 
 
Cell growth and/or maintenance 
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Table 3.6 (Contd) 
Proteins Molecular classes  Molecular  Functions  Biological functions  
A. Up-regulated proteins    
Chain A, Fidarestat bound to human aldose reductase  Enzyme: Oxidoreductase Oxidoreductase activity Metabolism ; Energy pathways 
Glyceraldehyde-3-phosphate dehydrogenase Enzyme: Dehydrogenase Catalytic activity Metabolism ; Energy pathways 
Uracil DNA glycosylase DNA binding protein DNA binding DNA repair 
Eukaryotic translation initiation factor 4E isoform 2 Translation regulatory protein Translation regulator activity Protein metabolism 
Triosephosphate isomerase 1 Enzyme: Isomerase Isomerase activity Metabolism ; Energy pathways 
Phosphoglycerate mutase 1 (brain) Enzyme: Mutase Catalytic activity Metabolism ; Energy pathways 
Phosphoglycerate mutase 1 (brain) Enzyme: Mutase Catalytic activity Metabolism ; Energy pathways 
Similar to Chain , Heat-Shock Cognate 70kd Protein Chaperone Chaperone activity Protein Metabolism 
H3L-like histone DNA  binding protein DNA  binding     
 
Regt     Regulation of nucleobase, nucleoside, 
nucleotide, and nucleic acid metabolism 
B. Down-regulated proteins    
Heat shock protein 90kDa beta, member 1   Chaperone Chaperone activity Cell communication; signal transduction 
ATP citrate lyase isoform 1   ATPase ATPase activity Metabolism ; Energy pathways 
Moesin   Cytoskeletal protein Structural constituent of cytoskeleton Cell growth and/or maintenance 
Glutamine-fructose-6-phosphate transaminase 2   Enzyme: Aminotransferase Transaminase activity Metabolism ; Energy pathways 
Phenylalanyl-tRNA synthetase, alpha subunit   Enzyme: Ligase Ligase activity Protein metabolism 
C. Differentially regulated proteins    
Transformation upregulated nuclear protein Ribonucleoprotein Ribonucleoprotein 
 
  Regulation of nucleobase, nucleoside,       
  nucleotide and  nucleic acid metabolism 
Nicotinamide phosphoribosyltransferase precursor Cytokine Transferase activity   Anti-apoptosis 
Vimentin variant 3    Cytoskeletal protein 
 
Structural constituent of 
cytoskeleton 
Cell growth and/or maintenance 
 
Casein kinase II alpha 1 subunit isoform a   Serine/threonine kinase Protein serine/threonine kinase 
activity 
Signal transduction/Protein Modification 
SEC13-like 1 (S. cerevisiae), isoform CRA_b   Chaperone Chaperone activity Protein metabolism 
Tubulin, beta 2C   Enzyme: Hydratase Catalytic activity Metabolism ; Energy pathways 
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Table 3.6 (Contd) 
 
 
 
Proteins Molecular classes  Molecular  Functions  Biological functions  
A. Differentially regulated proteins    
Chain A, crystal structure of human peroxisomal   Enzyme: Hydratase Catalytic activity Metabolism ; Energy pathways 
Glyceraldehyde-3-phosphate dehydrogenase   Enzyme : Dehydrogenase Catalytic activity Metabolism; Energy pathways 
Glyceraldehyde-3-phosphate dehydrogenase  Enzyme : Dehydrogenase Catalytic activity Metabolism; Energy pathways 
Annexin A2, isoform CRA_c   Calcium binding protein  Calcium ion binding Signal transduction/Cell communication 
Cathepsin B  Cysteine protease Cysteine-type peptidase activity Protein metabolism; Apoptosis 
Chain A, Human Aldose Reductase Mutant L301m   Enzyme:Oxidoreductase Oxidoreducatase activity Metabolism ; Energy pathways 
Manganese-containing superoxide dismutase  Enzyme: Superoxide 
dismutase 
Superoxide dismutase activity Cell proliferation ; Anti-apoptosis ; Cell growth 
and/or maintenance in metabolism 
Chain A, structural and kinetic study of the differences 
between human and E.coli manganese superoxide dismutase  
Enzyme: Superoxide 
dismutase  
Superoxide dismutase activity Cell proliferation ; Anti-apoptosis ; Cell  
growth and/or maintenance 
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Figure 3.20 shows the functional distribution of the identified proteins plotted against 
the percentage of proteins related to the designated function. Based on the biological 
function identified using HPRD, the percentage of proteins was plotted against the 
designated function. The results show that the majority of the proteins identified were 
observed to be related to energy pathways (31.8 %), cell growth and maintenance 
(20.5 %).  
 
Figure 3.20: Functional distribution histograms of the identified proteins using HPRD 
database. (n=1 and p < 0). The x-axis represents the biological function and the Y - axis 
represents the percentage of proteins carrying out the respective functions. 
Note that the majority of the proteins identified were related to the function of cell 
growth and maintenance and protein metabolism pathways. 
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3.6.2 Bioinformatic analysis of the proteomic data 
The ingenuity Pathways Analysis (IPA) (Ingenuity® Systems) is a software that enables 
researchers to model, analyse and understand the complexity of the composite 
biological and chemical systems. In the present study, IPA was used to identify the 
molecular functions and pathways which correlate with the proteins identified by mass 
spectrophotometry after the treatment of hypoxia and serum deprivation as compared 
to the control. The ingenuity pathway analysis programme uses a knowledge base 
derived from the literature to relate gene products with each other based on their 
interaction and function and also links directly to the supporting references. Ingenuity 
allows a flexible search between multiple levels of biology with an ease to understand 
specific relationships between genes, molecular and cellular processes and diseases. 
The bio functions are grouped into three major categories: 
i. Disease and disorders  
ii. Molecular and cellular functions. 
iii. Physiological System Development and Function (Canonical pathways are 
grouped in metabolic pathways and signalling pathways).  
Functional pathways and networks most significant to the data set were identified 
from the IPA library of canonical pathways. Two parameters were taken into 
consideration for the identification of the most significant pathways. Firstly, the ratio 
of the number of proteins that map to the pathway divided by the total number of 
proteins that map to the canonical pathways. Secondly, Fisher’s exact test was used to 
calculate a p-value determining the probability that the association between the   
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proteins in the dataset and the canonical pathway is explained by chance alone        
(Table 3.7). Each of these networks was ranked by a score based on negative log of     
p-value. These scores ranked different networks based on its statistical significance.  
The results in figure 3.20 show the top bio functions such as i) Disease and disorders ii) 
Molecular and cellular functions and iii) Physiological System Development and 
Function and iv) Canonical pathways related to the identified proteins. The biomarker 
analysis was carried out by applying filters specific to human species with respect to 
cancer provided a list of 17 specific proteins as potential biomarkers. The results 
demonstrated in table 3.8 include the name, location and fold change in the 
expression of the proteins observed in answer to micro-environmental changes 
(undifferentiated state). 
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Table 3.7: Top bio functions as generated by IPA. (Data obtained by considering 
negative log value of p, n=3). 
Values are based on the negative log of p-value computed using a right tailed  
Fisher's exact test. 
Top Bio Functions 
Diseases and Disorders                                                                                        p-value 
1 Cancer 2.00 x 10-9 - 4.61 x 10-2 
2 Gastrointestinal Disease 2.00 x 10-9 - 4.61 x 10-2 
3 Skeletal and Muscular  Disorders 1.15 x 10-6 - 3.03 x 10-2 
4 Genetic Disorder 5.62 x 10-6 - 4.61 x 10-2 
5 Neurological Disease 5.62 x 10-6 - 2.49x 10-2 
Molecular and Cellular Functions 
1 Cell Cycle 4.18 x 10-4 - 4.90 x 10-2 
2 Carbohydrate Metabolism 7.51 x 10-4 - 1.63 x 10-2 
3 Cell Death 2.45 x 10-3 - 4.90x 10-2 
4 Cellular Assembly and Organisation 2.05 x 10-3 - 3.42 x 10-2 
5 Cellular Compromise 2.05 x 10-3 - 1.02 x 10-2 
Physiological System Development and Functions 
1 Cell Mediated-Immune Response 2.05x 10-3 - 2.05 x 10-3 
2 Haematopoiesis 2.05x 10-3 - 2.05 x 10-3 
3 Tumour Morphology 2.05x 10-3 - 2.05 x 10-3 
4 Connective Tissue Development & Function 4.09 x 10-3 - 3.42 x 10-2 
5 Immune Cell Trafficking 8.16 x 10-3 - 8.16 x 10-3 
Top Canonical Pathways 
1 Glycolysis/Gluconeogenesis 9.73 x 10-7 
2 14-3-3-mediated Signalling 1.44 x 10-3 
3 Fructose and Mannose Metabolism 4.85 x 10-3 
4 Breast Cancer Regulation by Stathmin1 6.23 x 10-3 
5 Inositol Metabolism 1.02 x 10-2 
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Figure 3.21 shows the graph obtained by the functional network analysis by IPA software. The data in graph A shows the number of proteins associated 
with the respective diseases and disorders. Graph B represents the molecular and cellular functions of the identified proteins. Graph C shows the 
proteins associated with the Physiological System Development and Functions and graph D represents the canonical pathways related to the identified 
proteins. 
        A                                                                                                                             B 
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Figure 3.21: Functional network analysis by IPA.Top 5 (A) Diseases and disorders,  (B) Molecular and cellular functions, (C) Physiological System Development 
and Functions and (D) Canonical pathways (n = 1 , p < 0). 
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Table 3.8: shows the 17 potential biomarkers in cancer from the protein dataset using IPA analysis (n = 1). 
Summarised in the table 3.8 are the potential markers identified in cancer. The majority of the markers are localised in the cytoplasm of the cells. 
The fold change in the protein expression level signifies its subsequent up and down-regulation on induction of micro-environmental changes. 
Majority of the proteins displayed an upregulated expression profile on induction of hypoxia and serum deprivation.  These proteins were further 
subjected to biomarker analysis to study their significance cancer pathways. 
 
  Proteins    Locations                Fold changes 
   
    Aldolase A, fructose-biphosphate   Cytoplasm     1.780 
    ATP citrate lyase   Cytoplasm     1.000 
 Annexin A2 Plasma Membrane -1.120 
 Casein kinase 2, alpha 1 polypeptide Cytoplasm -1.070 
 Collagen, type VI, alpha 2 Extracellular Space   1.260 
 Eukaryotic translation initiation factor 4E Cytoplasm     2.560 
 Glyceraldehyde-3-phosphate dehydrogenase Cytoplasm   1.240 
 Heat shock 70kDa protein 8 Cytoplasm   1.240 
 Heat shock protein 90kDa beta (Grp94),  Cytoplasm -1.200 
 Heterogeneous nuclear ribonucleoprotein  Nucleus -1.160 
 Nicotinamide phosphoribosyltransferase Extracellular Space -1.180 
 Phosphoglycerate kinase 1 Cytoplasm   1.040 
 Triosephosphate isomerase 1 Cytoplasm   1.210 
 Tubulin, alpha 1a Cytoplasm   1.560 
Tubulin, beta 2C Cytoplasm -1.090 
 Superoxide dismutase 2, mitochondrial Cytoplasm -1.420 
 Vimentin Cytoplasm   1.180 
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The analysis of the proteins from the database did not generate any specific pathway 
through the IPA software. However, on applying a filter specific to human species and 
cancer generated a network involving 11 proteins from the dataset. The network was 
thereafter overlayed with a set of ingenuity biomarkers in order to identify potential 
biomarkers for the identification of glioma stem cells. The network displayed in          
Fig. 3.21 directs study to explore vimentin (Vim), heterogeneous nuclear riboprotein K 
(HNRNPK) and eukaryotic translation initiation factor 4e (EIF4e) as potential 
biomarkers for the identification of stem cells. The coloured ellipses within the cell 
denote the proteins involved in the network and their localisation within the cell. Large 
ellipses outside the cell represent the type of cancer linked to the expression of the 
respective protein. 
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Figure 3.22 shows the self – designed network created using IPA knowledge database. The coloured ellipses within the cell denote the proteins involved 
in the network and their localisation within the cell. Large ellipses outside the cell represent the type of cancer linked to the respective protein.   
 
 
 
                
Figure 3.22;  Network generated by IPA path designer overlayed with cancer biomarkers from ingenuity knowledge database. 
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Stem cells are considered to be the most primordial cells in the human body that 
impart plasticity to the organ system (Sabetrasekh et al., 2006). The characteristic 
features which interests researchers in exploring stem cells are their self-renewal 
potential and the ability to proliferate into diverse cell types (Singh et al., 2003). Stem 
cells have been extensively explored for their use in the field of developmental 
medicine, repair, gene therapy and transplant communities (Sabetrasekh et al., 2006). 
Despite its therapeutic potential, tumour initiating stem cells (CSCs) have been known 
to trigger cancer. CSCs comprise of a small sub-group of cells within a tumour and are 
essential to its growth. The origin of CSCs still remains unclear leaving an open end 
justification that on acquiring a mutation or change in their DNA instructions could 
disturb their self-renewal control. In addition, the immediate progeny of stem cells 
(progenitors) due to genetic damage could regain the power of self-renewal instead of 
developing into mature cells. Overall, the resistive potential of CSCs towards 
chemotherapeutic agents and their ability to form tumours have given rise for a need 
to identify and understand the mechanisms of resistance. In addition, it is very 
important to predict the outcome and response to cancer treatment (Woodward and 
Sulman, 2008). Discrimination of CSCs by means of a biomarker can facilitate early 
diagnosis and help in reducing cancer-related mortality. Similar to other cancers, 
glioma is thought to be a disease of accumulated genetic alterations arising from 
transformed neural stem cells (Kitange et al., 2001; Singh et al., 2003). 
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Previous work carried out in our laboratory studied the expression profile of multi-
drug resistance genes and proteins in cancerous and stem cells (Lu, PhD thesis, 2008). 
This study focused on the characterisation of CD133+ glioma stem-like cells with 
respect to the expressions of multi-drug resistance mdr1 and bcl-2 (Lu, PhD thesis, 
2008).  A high level of MDR-related molecules such as P-gp and Bcl-2 support the 
significant chemoresistance of CD133+ glioma and normal cells compared to the 
corresponding CD133- cells. The study by Lu (2008) also indicated that the multi-drug 
resistance potential of CD133+ stem-like normal astrocytes was higher than the CD133+ 
glioma stem-like cells. Enrichment of CD133+ cells derived from the 
astrocytoma/oligodendroglioma (GOS-3) cells in serum deprivation indicate that CSCs 
could be enhanced by introducing micro-environmental changes (Lu, 2008).  
The present study focused on investigating the stem cell-like characteristics in the 
differentiated and undifferentiated glioma cells. Considering equal evidence in support 
of CD133+ and CD133- to generate tumours, the aim was to find a selective marker to 
define glioma stem cells and allow their distinction from NSCs. The novel approach of 
this study lies in assessing the expression profiles of two markers Oct4-A and BMP2 in 
glioma with respect to a well established undifferentiated stem cell marker CD133. 
Maintenance of an undifferentiated state is a key feature of stem cells, therefore 
monitoring the divergence in the differentiated and undifferentiated states in brain 
tumour cell lines would provide an insight regarding the altered regulatory 
mechanisms which leads to tumour formation, progression and chemoresistance. 
Evaluating stemness signatures in the differentiated and undifferentiated cells have 
been further explored by testing the chemo-resistive potential and cell cycle phases of 
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these cells. Finally, proteomic analysis carried out provides a dataset of proteins that 
have been altered in the process of differentiation of the U87-MG cells. 
Preliminary experiments assess the levels of protein CD133, Oct4-A and BMP2 in 
different grades of glioma cell lines (1321-N1, GOS-3 and U87-MG). Genomic analysis 
carried out using qRT-PCR indicated an absence of the CD133 gene in all the three 
grades of glioma cell lines. A minimal level of Oct4-A expression was observed in all the 
three cell lines with a slightly higher expression level noticed in the GOS-3 glioma cell 
line. The expression of the BMP2 gene remained restricted to only U87-MG cells. The 
statistical analysis performed using Student’s one sample T-test did not indicate any 
significant difference in the expression of candidate genes within the glioma cell lines. 
However, the minimal level of expression of Oct4-A and BMP2 was still taken into 
consideration due to limited marker protein expression by the stem cells. 
The analysis carried out using the flow cytometer and immunofluorescent studies, 
indicated an absence of CD133 and BMP2 protein in the three tested glioma cell lines. 
The GOS-3 cell line showed the highest level of Oct4-A protein (84.3 %), followed by 
1321-N1 (75.6 %) and U87-MG (72.7 %). The results showed a significance difference 
observed in the expression of Oct4-A protein (* p < 0.05) in the GOS-3 and U87-MG 
cells as compared to the 1321-N1 cells. This analysis contributed to the study of the 
protein expression profiles in the differentiated glioma cells. Based on the literature 
search and evidence of finding CD133 cells in U87-MG cell lines (Wong et al., 2009), 
further work was carried out on cell differentiation, chemosensitivity, cell cycle 
analysis and proteomics using U87-MG cells. 
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U87-MG cells were subjected to two different micro-environmental changes in order 
to enhance their state of undifferentiation and enrich its stemness. Glioma cells when 
subjected to hypoxia showed an elevated expression of CD133 protein with an 
increase in self-renewal potential and inhibition of their differentiation                   
(Soeda et al., 2009). In addition, the cells located in the intra-tumoral areas augmented 
with hypoxia elicit CD133 surface protein along with an expression of DNA repair 
protein O6-methylguanine-DNA-methyltransferase (MGMT) (Pistollato et al., 2010). 
Hypoxia regulates stem cell phenotype with subsequent induction of specific tumour 
stem cell-related genes (Seidal et al., 2010). Therefore, cells residing in the hypoxic 
environment could be characterised with noticeable stem cell features and further 
examined for chemoresistance. U87-MG cells were subjected to 100 % nitrogen 
atmosphere for 30 min in order to induce hypoxia and were analysed after 24 hrs of 
incubation for the expression of stem cell-related proteins CD133, Oct4-A and BMP2. 
After incubation, the cells attained a spherical morphology when observed under a 
light microscope (x 20 magnification). Oct4-A protein level was significantly (* p < 0.05) 
induced by   14 % due to hypoxia with a basal expression of CD133 (2.3 %) protein in 
the hypoxic U87-MG cells. An in vivo model in adult mouse previously demonstrated 
that the germ line-specific transcription factor Oct4 is sufficient to generate 
pluripotent stem cells from NSCs (Kim et al., 2009). Furthermore, the existence of Oct4 
protein in lung cancer plays a crucial role in maintaining pluripotency and supports the 
chemoresistive potential of lung cancer derived CD133+ cells (Chen et al., 2008). An 
elevated expression of Oct4-A protein along with a marginal expression of CD133+ 
stem-like cells could therefore indicate a development of stem cell-like characteristics 
in the undifferentiated hypoxic U87-MG cells as compared to the control. However, 
the results do indicate the existence of stem cells on the basis of Oct4-A expression. 
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 Cancer cells adjust to the serum-deprived environment and display a down-regulation 
of genes associated with neural mature markers with a subsequent up-regulation of 
genes which are related to primitive NSC markers (Kang et al., 2006). In addition to 
high drug resistance and an enhanced proliferative potential, these dedifferentiated 
cells also exhibit important proliferation signalling proteins, primitive neural lineage-
related proteins, cancer genes, and transporter genes which may contribute towards 
cancer and its aggressiveness (Kang et al., 2006). Another attempt to induce 
undifferentiation in U87-MG cells was carried out by induction of serum deprivation 
supplemented with growth factors hEGF and bFGF (Stem Cell Sciences, UK). A 
quantitative measurement of the candidate proteins showed a significant (* p < 0.05) 
decrease in the Oct4-A protein level by 26.7 % as compared to the control cells. Similar 
to the control U87-MG cells, serum-deprived cells did not exhibit the expression of 
CD133 and BMP2 proteins. Flow cytometric results were further confirmed by 
immunofluorescent studies. Although, microscopic observation showed a neurospheric 
morphology indicating a state of undifferentiation, a down-regulation of Oct4-A and 
the absence of CD133 protein indicated an absence of stemness characteristics in the 
serum-deprived cells. Inconclusive results have been drawn from the use of 
chemotherapy targeted against cancer proliferation and reoccurrence.  By virtue of 
different molecular mechanisms such as cell cycle kinetics, DNA replication and repair 
mechanisms, asynchronous DNA synthesis, anti-apoptotic proteins and transporter 
proteins, stem cells resist the effect of potent chemotherapeutic agents (Wicha et al., 
2006). In addition to MDR, multi-drug associated proteins (MRP) offer defence against 
xenobiotics and endogenous toxic metabolites, leukotriene-mediated inflammatory 
responses, as well as protection from the toxic effect of oxidative stress (Shervington 
and Lu, 2008; Bakos and Homolya, 2007). Effective chemotherapeutic drugs such as 
 
 
  
 
 
 
 
   
141 
 
Taxol and TMZ were used to check the chemosensitivity of differentiated and 
undifferentiated U87-MG cells. Taxol mediates a strong cytotoxic and anti-proliferative 
activity in malignant glioma cell lines (Roth et al., 1998) whereas, CD133+ stem-like 
cells have been found to be resistant towards Taxol (Dey et al., 2010). On treatment 
with TMZ, glioma cells undergo G2/M arrest and die due to autophagy (Kanzawa et al., 
2003; Zeng et al., 2007). However, CD133+ cells in glioma withstand the toxic effect of 
TMZ by involving cell cycle regulating proteins CHK1/CHK2 (Hambardzumyan et al., 
2006). The cytotoxic effect of Taxol remained unchanged for the control and hypoxic 
U87-MG cells, by killing approximately 9 % of cells from the entire population. A 
significant (* p < 0.05) fourfold increase in cytotoxicity was observed in serum-
deprived U87-MG cells accounting for 36 % of cell death. On the other hand, TMZ 
displayed an overall weak cytotoxic effect on the U87-MG cells. As compared to the 
control cells (6 %), the percent of cell death was reduced to 3 % in the hypoxia-treated 
cells. However, the number of dead cells increased to more than threefold                      
(26 %, * p < 0.05) on serum deprivation. Cellular differentiation showed that Taxol is a 
better chemotherapeutic drug compared to TMZ. Since, previous data from our lab 
have demonstrated the multi-drug resistance ability of CD133+ cells with the co-
expression of anti-apoptosis related molecules such as P-gp and Bcl2 (Lu, 2008), the 
chemoresistance of the hypoxic U87-MG cells could, therefore, be attributed to the 
existence of a subset of CD133+ cells. Hence, the overall effectiveness of the cytotoxic 
drugs was more noticeable in the U87-MG cells deprived of serum which displayed 
neurospherical morphology but did not exhibit any stem cell-related properties. 
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Chemotherapeutic drugs limit cancer growth by blocking one or more stages of cell 
cycle. The serum-deprived U87-MG cells showed a significant (* p < 0.05) difference in 
the G1, S and G2 phase of the cell cycles as compared to the control. A similar                 
(* p < 0.05) change in the cell cycle phase was observed when the serum-deprived cells 
were treated with taxol. A prominent G2/M arrest in the cell cycle phase of control 
(46.4 %) and hypoxic (56.1 %) cells was observed when treated with Taxol. TMZ 
induced a G1 phase arrest in the U87-MG cells line, where the maximum arrest was 
observed in the serum-deprived cells (59 %, * p < 0.05) followed by a similar response 
in the hypoxic (47.2 %) and control cells (44.8 %). The S-phase of the serum-deprived 
was highly and significantly (* p < 0.001) affected on account of TMZ treatment.  
While Taxol was more effective in blocking the G2/M phase of hypoxia-treated        
U87-MG cells, serum-deprived cells showed a prominent block of the G1 phase 
irrespective of the treatment with Taxol and TMZ. The present data suggest that 
though TMZ induced a G1 phase arrest in the control, hypoxic and serum-deprived 
cells, Taxol was equally capable of arresting the serum-deprived cells in the G1 phase. 
The probable reason for cell-killing by Taxol could be the induction of apoptosis by 
internucleosomal DNA fragmentation (Sui et al., 2004).  This finding could be 
investigated further to study the sensitisation of serum-deprived cells towards Taxol by 
considering the mitochondrial pathway mediated apoptosis (Goyeneche et al., 2006). 
The proteomic approach in this study helps to organize the alteration in the tumour 
related protein levels and identify new therapeutic targets and biomarkers correlated 
to cancer   (Zhang et al., 2010). In the present study, proteomics was used to monitor 
the changes at the cellular protein level in the differentiated and undifferentiated U87-
MG cells and to define selective biomarkers for the identification of glioma stem cells. 
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The experiments involved 2D-DIGE for the separation of proteins which favours 
minimal inter-gel variation and MALDI-TOF for protein identification. Approximately, 
96 protein spots listed by 2D-DIGE were found to be differentially expressed, out of 
which 44 spots were selected for identification (These 44 spots were highly up, down 
or differentially regulated as compared to the others. All of the spots could not be 
identified due to limited consumable money allotted). The up-regulated spots showing 
a 2.0 fold increase, the down-regulated spots showing a 1.0 fold decrease and the 
differentially regulated spots with a 4.5 fold increase were selected for protein 
identification using MALDI-TOF. All the 44 spots were identified with a high confidence 
level of 100 %, 37 of 44 spots were confidently identified as human proteins. Based on 
the biological function of the proteins, they were grouped into 9 categories: 
metabolism and energy pathways (n = 14), cell growth and maintenance (n = 9), 
protein metabolism (n = 6), signal transduction (n = 5), nucleic acid metabolism (n = 4), 
anti-apoptosis (n = 3), cell proliferation (n = 2), DNA repair (n = 1) and unknown (n = 1). 
(n = number of proteins related to the respective function). 
Up-regulated proteins  
On induction of hypoxia and serum-deprivation, 24 proteins were found to be              
up-regulated. The majority of the up-regulated proteins (n = 9) participated in 
metabolism and energy pathways. Amongst them, protein CLN2 is a cyclin involved in 
cell cycle regulation promoting G1 to S phase transition. Fructose-biphosphate 
aldolase A is an enzyme involved in glycolysis abundantly expressed in 
oligodendroglioma (Park et al., 2008). ATP binding enzyme Selenophosphate  
synthetase 1 affects cell viability upon ionizing radiation through modulation of p53 
activity (Chung et al., 2006). Phosphoglycerate kinase 1 (PGK1) is a glycolytic enzyme 
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catalyzing the conversion of 1, 3-diphosphoglycerate to 3-phosphoglycerate. In 
contrast, fidarestat is a human aldose reductase (hAR) inhibitor which catalyzes the 
reduction of different compounds such as aldehydes, xenobiotic aldehydes, ketones 
and trioses with nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor. 
It blocks glucose metabolism in cancer cells (Fournier et al., 2009). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is a glycolytic enzyme over expressed in many 
tumours and induced by hypoxia in normal and malignant cells (Said et al., 2007). 
Another glycolytic enzyme Triosephosphate isomerase 1 (TPI1) serves as an essential 
factor for the production of energy for cells. A variant of Triosephosphate isomerase 1 
has also been detected in late passages of glioblastoma cells using proteomic analysis 
(Khalil and Madhamshetty, 2006). Two different forms of the glycolytic enzyme 
phosphoglycerate mutase 1 (PGM1) were observed on treatment with hypoxia and 
serum deprivation. In tumour cell lines PGM1 is known to regulate the balance 
between glycolysis and another ATP-producing pathway, glutaminolysis (Engel et al., 
2004). 
The proteins related to cell growth and maintenance (n = 5) include Alpha 2 type VI 
collagen isoform 2C2 precursor, Laminin A/C isoform 2, Vimentin , Alpha-tubulin and 
Capping protein muscle Z-line (actin-filament), beta. Alpha 2 type VI collagen isoform 
2C2 precursor basically functions as a cell binding protein whereas the Laminin isoform 
2 is abundantly expressed in gliomas promoting integrin mediated glioma cell 
migration and glioma invasion (Kawataki et al., 2007). Vimentin is the major subunit 
protein of the intermediate filaments involved with the intracellular transport of 
proteins between the nucleus and plasma membrane. It was found to be present in 
high levels in the non-invasive and non-infiltrative tumours and appeared to be a 
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discriminative marker for clustering infiltrative and/or invasive meningiomas versus 
non-invasive meningiomas (Bouamrani et al., 2010). A 3.5 fold up-regulation of 
vimentin may indicate the aggressiveness of glioma cells when shifted towards an 
undifferentiated state. The expression of cytoskeletal protein alpha tubulin in its 
nitrated form has been extensively found in a progressive neoplasm indicating 
advancement in the tumour grade (Fiore et al., 2006). The capping protein muscle Z-
line up-regulation marks the onset of cellular assembly in the undifferentiated U87-MG 
cells (Cooper and Sept, 2008). 
Proteins involved in cell communication and signal transduction include Heat shock 
protein 90kDa beta (Hsp90β) and Protein phosphatase 2, beta isoform. Hsp90β is a 
molecular chaperone stabilizing Akt (serine/threonine protein kinase) and oncogenic 
forms of mutant epidermal growth factor receptor, both of which favour the growth of 
a variety of cancers including gliomas (Basso et al., 2002 and Lavictore et al., 2003). 
Protein phosphatase 2, beta isoform is implicated in the negative control of cell growth 
and division. In addition Poly(rC) binding protein 3 isoform 1 and H3L-like histones 
were reported as proteins regulating the nucleobase, nucleoside, nucleotide, together 
with nucleic acid metabolism. Poly(rC) binding protein 3 isoform 1 functions as a 
cytosolic iron chaperone in the delivery of iron to ferritin (Shi et al., 2008). H3L-like 
histones are basic nuclear proteins maintaining the nucleosome structure of the 
chromosomal fiber. Hsp70 is an anti-apoptotic protein found to be elevated in various 
types of cancer. Stress conditions up-regulate Hsp70 levels through transcriptional 
activation, preferential translation and mRNA stabilization and restrains apoptosis by 
inhibiting aggregation of cell proteins (Lindquist et al., 1988 and                       
Calderwood et al., 2005). EIF4e isoform 2 is involved in enhancing translational 
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efficiency, splicing, mRNA stability, and RNA nuclear export. EIF4e isoform 2 can 
function as an oncogene and its activation may be a key event in oncogenic 
transformation by phosphoinositide-3 kinase and Akt (Ruggero et al., 2004). HPRD 
analysis revealed that an unknown protein product detected together with Hsp70 and 
EIf4e) isoform 2 undertake the function of protein metabolism. Furthermore, DNA 
repair protein Uracil DNA glycosylase (UDG) functions to suppress the GC-to-AT 
transition mutations (Caradonna and Muller-Weeks, 2001).  
An up-regulation in the expression of the stem cell marker protein suggests a state of 
undifferentiation. In addition to CD133, stemness signature has been identified by an 
up-regulation of several marker proteins namely nestin, mushashi, Sox2, PTEN, Oct4 
and BMPs (Bao et al., 2006; Dasari et al., 2010). The proteomic data disclosed different                     
up-regulated proteins (n = 3), whose elevated expression was observed more under 
serum-deprived conditions. Laminin binding protein was up-regulated by a 9.8 fold in 
serum-deprived cells as compared to the hypoxic cells. Laminin promotes tumour 
angiogenesis by providing appropriate signals and structure required for endothelial 
cell attachment and proliferation (O’Brien et al., 2001; Croft et al., 2004). In glioma, 
laminins also regulate pathways which support growth, invasion, and resistance to 
chemotherapeutic drugs (Keivit et al., 2010). The laminin receptor Integrin α6β1 
directly regulates their tumorigenic capacity, anchoring the adult neural stem cells to 
the niche vasculature (Corsini and Martin-Villalba 2010). The condition of serum 
deprivation would prepare U87-MG cells for increased proliferation and 
chemoresistance, a measured approach to acquiring stemness. UNG (gene coding UDG  
protein) expression is regulated by the cell cycle and its enhanced activity is observed 
in proliferating cells as compared to the non-proliferating cells (Nagelhus et al., 1995; 
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Walsh et al., 1995 and Aprelikova and Tomilin, 1982). A study carried out on the 
survival of embryonic rat hippocampal neurones suggests that depletion of UNG 
results in a DNA damage response, inducing p53-dependent apoptosis (Kruman et al., 
2004). By means of transcription-coupled repair (TCR) pathway, differentiated cells 
undertake the repair of transcribed genes (Nouspikel and Hanawalt., 2004). Base -
excision repair (BER) is one such mechanism involved in TCR maintaining genomic 
integrity in the brain initiated by UDGs (Le et al., 2000). Under ischemic conditions 
uracil misincorporated DNA damage is compensated by an up-regulation of UNG and 
uracil-BER activity and holding up the genomic stability within brain (Kruman et al., 
2004).  The increase in the level of UDG in hypoxia as well serum-deprived U87-MG 
cells from fold 1.2 - 6.5, signifies a DNA repair mechanism. This further indicates that 
the majority of the serum-deprived cells are residing in the phase of differentiation as 
compared to the hypoxic cells. 
The dinucleotide poly phosphates (Ap4A) rise in response to stress conditions 
contributes to cell proliferation, DNA repair and replication, vasotone regulation and 
neurotransmission (Baxi and Vishwanatha, 1995). In HeLa cells, it is found that UDG 
and GAPDH are an Ap4A binding proteins targeting DNA repair/replication (Meyer-
Siegler et al., 1991). GAPDH is extensively expressed in tumours and during phases of 
cell cycle which require more energy. Cytosolic expression of GAPDH does not 
correspond to cell death. GAPDH displays other activities, such as uracil DNA 
glycosylase activity that mediates DNA repair and binding to transfer RNA and DNA 
(Sawa et al., 1997). 
A prominent over expression of GAPDH by 11.1 fold was observed in the serum-
deprived cells as compared to the hypoxic U87-MG cells. The in-vitro analysis of 
GADPH expression was not found to be induced or regulated under hypoxic conditions 
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(Said et al., 2007). Serum-deprived cells showed a cytosolic GAPDH colocalised with 
stress fibres indicating a specialised function of GAPDH for its interaction with 
cytoskeletal elements, apart from the normal glycolytic function                            
(Schmitz and Bereiter-Hahn, 2001). The use of GAPDH as a housekeeping should also 
be revisited due to differential expression pattern under conditions of hypoxia and 
serum deprivation compared to the control U87-MG cells. 
In this study the overall several fold increases in the levels of the up-regulated proteins 
were more prominent in the serum-deprived cells as compared to the hypoxic cells. 
Serum-deprived cells exhibit an increased demand of energy production due to low 
glucose availability. The tendency of the serum-deprived cells to form neurospheres 
correlates with an enhanced expression of cytoskeletal proteins such as laminin A/C 
isoforms 2, vimentin, alpha tubulin and capping protein muscle Z-line beta contributing 
to the structural alteration in the undifferentiated U87-MG cells. The expressions of 
proteins related to heat shock response and DNA repair further prepare the 
dedifferentiating cells against stress conditions of serum starvation and low oxygen 
levels. 
Down-regulated proteins  
In the present study the proteomic analysis disclosed down-regulated proteins (n = 5) 
amongst which Hsp90β was detected with a 1.5 fold decrease in the expression level. 
Metabolism and energy pathway related proteins included ATP citrate lyase (ACL) 
isoform 1 and  Glutamine-fructose-6-phosphate transaminase 2 (GFPT2). ACL isoform 1 
converts glucose-derived citrate into acetyl-CoA. ACL activity is an essential factor 
linking growth factor-induced increases in nutrient metabolism to the regulation of 
histone acetylation and gene expression (Wellen et al., 2009). GFPT2 is the first                      
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rate-limiting enzyme of the hexosamine biosynthesis pathway mainly expressed in the 
central nervous system. Sub-membranous cytoskeletal protein moesin function in   
cell-cell recognition, signalling and for cell movement. Enzyme phenylalanyl-tRNA 
synthetase, alpha subunit, performing a ligase activity is involved in protein 
metabolism. 
Down-regulation of ACL indicates a progress in the state of differentiation in the 
glucose dependent cells (Hatzivassiliou et al., 2005). Thus, it is perceptible to notice a 
1.4 fold decrease in the expression of ACL in serum-deprived cells as compared to 
ischemic cells which are non-glycolytic having less dependency on ACL activity. As 
observed in pancreatic cancer, reduction in the level of moesin could result in 
increased migration, invasion and metastasis promoting cellular translocation of         
β-catenin, and re-distribution and organization of the cytoskeleton                            
(Abiatari et al., 2010). In addition to anaplastic carcinoma, moesin could also function 
as a phenotypic marker for undifferentiated glioma cells. Phenylalanyl-tRNA 
synthetase is expressed in a tumour-selective and cell cycle stage- and differentiation-
dependent manner (NCBI). A marked decrease in the expression level, therefore, 
denotes a possible shift towards the state of undifferentiation and tumour 
progression. 
 
Differentially expressed proteins 
The proteomic analysis in this study have also shown differentially expressed proteins 
(n = 15) including five proteins related to metabolism and energy pathways. Two 
isoforms of GAPDH were increased by fold 9.3 and 5.6, respectively, in the serum-
deprived cells as compared to the hypoxic sample. Tubulin, beta 2C forms the major 
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constituent of the microtublues. Its molecular functions include guanosine 
triphosphate (GTP) and unfolded protein binding and regulating GTPase activity. Chain 
A, crystal structure of human peroxisomal delta 3, 5, delta 2,     4-dienoyl Co-A 
isomerase carries out isomerisation of 3-trans, 5-cis-dienoyl-CoA to      2-trans, 4-trans-
dienoyl-CoA. In addition to protein binding and isomerase activity, it is also involved in 
fatty acid-beta oxidation and generation of precursor metabolites and energy. Another 
molecule related to metabolism and energy pathways is Chain A, Human Aldose 
Reductase Mutant L301m complexed with sorbinil which performs the oxidoreductase 
activity. 
Vimentin variant 3 showed a 5.3 fold increase in its expression level in the serum-
deprived U87-MG cells, responsible for the function of cell growth and maintenance. 
Casein kinase II alpha 1 (CSNK2A1) subunit isoform A is a serine/threonine protein 
kinase that phosphorylates acidic proteins such as casein. Casein kinases are known to 
have a regulatory function in cell proliferation, cell differentiation and apoptosis. In 
addition to phosphorylation of various key intracellular signalling proteins involved in 
tumour suppression (protein 53; p53-tumour suppressor protein and phosphatase and 
tensin homolog; PTEN- tumour suppressor gene) and tumorigenesis (myc - oncogene, 
jun - oncogene, nuclear factor kappa-light-chain-enhancer of activated B cells;           
NF-kappaB - DNA transcription control). CSNK2A1 is also considered to influence Wnt 
signalling via beta-catenin phosphorylation and the PI 3-K signalling pathway via Akt 
phosphorylation. Annexin A2, isoform CRA_c is a protein regulating cell growth and 
signal transduction pathways. In addition to protein modification, Annexin A2 is 
considered to play a role in eliciting heat shock response. Transformation up regulated 
nuclear protein is a conserved RNA-binding protein involved in various processes of 
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gene expression including chromatin remodelling, transcription, mRNA splicing, 
translation, and stability. This protein is important for cell migration and metastasis 
and also participates in cell cycle progression (Dejgaard et al., 1994; Inoue et al., 2007). 
Protein metabolism-related proteins comprised of SEC13-like 1 (S. cerevisiae), isoform 
CRA_b and Cathepsin B. SEC13-like 1 (S. cerevisiae), isoform CRA_b is a part of 
endoplasmic reticulum and the nuclear pore complex and functions in protein 
transport. Cathepsin B (CSTB) gene is over expressed in a variety of cancer such as 
lung, prostate, colon, breast, and stomach (Hughes et al., 1998). Analysis of cytosolic 
accumulated CSTB in mouse hepatocytes and rat hepatoma cells has implicated its 
contribution in TNFA-induced apoptosis (Guicciardi et al., 2000). Nicotinamide 
phosphoribosyltransferase precursor (NAMPT) catalyses one step in the biosynthesis 
of nicotinamide adenine dinucleotide (Ramsey et al., 2009). This anti-apoptotic protein 
promotes vascular smooth muscle cell maturation and inhibits neutrophil apoptosis. 
Two forms of manganese-containing superoxide dismutases involved in cell 
proliferation and maintenance were found to be up-regulated by 2.7 and 4.0 fold, 
respectively, in the serum-deprived cells. Manganese-containing superoxide dismutase 
binds to the superoxide by-products of oxidative phosphorylation and converts them 
to hydrogen peroxide and diatomic oxygen. It destroys biologically toxic radicals which 
are normally produced within the cells.  
Differential expression indicated a down-regulation of proteins under hypoxic 
conditions (scale -1.0 to -1.4) and an apparent increase under serum-deprived 
conditions (scale 3.1 to 10.3). Since a total of 15 proteins have been identified as 
differentially regulated, it could be deduced that hypoxia and serum deprivation shift 
the cells towards an undifferentiated state via different approaches. While serum 
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withdrawal enhances the need for metabolism and cell growth related proteins, 
hypoxic cells express its subsequent down-regulation. A similar expression profile was 
observed for proteins involved in protein metabolism, signal transduction,                 
anti-apoptosis and regulation of nucleotides. 
 
The IPA compare analysis confirmed an identical protein expression profile in the 
hypoxia-treated cells and the serum-deprived cells with reference to the U87-MG 
control cells. The IPA software further helped in analysing the role of identified 
proteins in various diseases and disorders, top molecular and cellular functions, 
physiological system development and top canonical pathways. Treatment with 
hypoxia and serum deprivation modulated cancer at the top most level, indicating that 
the state of undifferentiation plays a crucial role in oncogenesis. The other disease and 
disorders included gastrointestinal disease, skeletal and muscular disorders, genetic 
disorder and neurological disease. The cellular and molecular functions affected 
include cell cycle, carbohydrate metabolism, cell death, cellular assembly, organisation 
and cellular compromise. In line with the experiments performed in the 
undifferentiation state of U87-MG cells, the proteins involved in altering the cell cycle  
phases could provide an insight into discriminating the regulatory mechanism of the 
differentiated and undifferentiated glioma cells. The identified proteins affected the 
physiological functions such as Cell mediated-immune response, Haematopoiesis, 
Tumour morphology, Connective tissue development and function and Immune cell 
trafficking. The records of canonical pathways displayed that 
glycolysis/gluconeogenesis, 14-3-3-mediated signalling, fructose and mannose 
metabolism, breast cancer regulation by stathmin1, inositol metabolism were the top  
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five pathways affected on induction of micro-environmental changes. A detailed 
investigation of above mentioned parameters with respect to the micro-environmental 
changes induced in glioma cell lines could probably provide evidence to the 
contribution of hypoxia and serum deprivation in maintaining stem-like cells and 
promoting tumour formation and relapse.  
Biomarker analysis carried on the protein dataset by applying filters specific to human 
species and cancer, proposed a total of 17 proteins identified as potential biomarkers 
(Table 3.8). Furthermore, a functional protein association network for proteins that 
were differentially expressed due cellular undifferentiation was generated using IPA. 
The network was overlayed to an inbuilt biomarker library generated in the IPA 
knowledgebase. The network, thus, generated 11 proteins namely Vimentin, PGK1, 
EIF4e, GAPDH, CSNK2A1, Hsp90β1, HNRNPK, ANXA2, HspA8, TPI1 and NAMPT. The 
identification of these 11 proteins narrows down the research focus to explore in 
detail the expression profiles of these proteins in the undifferentiated U87-MG glioma 
cell line in order to define selective alternative marker/s for CSCs in addition to CD133. 
Vimentin is involved in a variety of cancers including prostatic carcinoma, efficacy and 
diagnosis of non-small lung and pancreatic cancer, colorectal cancer, transitional cell  
carcinoma and in the prognosis and progression of breast cancer(Katsumoto et al., 
1990). Vimentin is the major intermediate filament cytoskeletal protein playing an 
important role in cell movement and motility (Katsumoto et al., 1990). It belongs to 
glioma specific extracellular matrix components and is implicated in both neo-
vascularisation and invasion of malignant glial cells (Zhang et al., 2006).  Constitutive 
coexpression of vimentin with casein kinase in prostate cancer cell lines is linked with 
an invasive phenotype that can be reversed by reducing vimentin expression (Singh et 
al., 2003). Hypoxic conditions have been known to cause redistribution of vimentin to 
 
 
  
 
 
 
 
   
154 
 
a more insoluble and extensive filamentous networks that could play a role in 
endothelial barrier stabilization. Redistribution of vimentin is mediated through 
altering the phosphorylation of the protein and its interaction with HSP27 (Liu et al., 
2010).  However, growth factors such as bFGF have been found to control the 
cytoskeletal network by up-regulating vimentin under conditions of serum deprivation           
(Bramanti et al., 2006). Proteomic analysis revealed that two different forms of 
vimentin were up-regulated by a magnitude of 3 - 5.3 fold in the serum-deprived cells 
as compared to the hypoxic U87-MG cells.  
In addition, vimentin is linked directly to PGK1, CSNK2A1 and EIF4e. HIF1α-regulated 
gene PGK1 was strongly up-regulated in non-stem glioma cells under hypoxia as 
compared to glioma stem cells (Keith and Simon, 2007). The expression profile 
observed in serum-deprived cells was 6.5 fold higher as compared to the hypoxia -
treated cells indicating that the majority of the serum-deprived cells did not exhibit 
stem cell-related proteins. PGK1 can be adopted as a marker in future experiments for 
the isolation of differentiated glioma cells, thus, favouring isolation of the stem-like 
cells. CSNK2A1 is considered as immuno-histochemical astrocytic marker is responsible 
for processes such as cell proliferation, differentiation, apoptosis and tumour 
development (Kramerov et al., 2006). An approximate 6.5 fold of CSNK2A1 in serum-
deprived cells as compared to hypoxia, thus, demonstrates a more proliferative nature 
of serum-deprived cells. CSNK2A1 is also noted to be linked with the down-regulated 
expression of Hsp90β1 in the undifferentiated as compared to the control, signifying 
an alteration in the cell cycle phases and increased chemosensitivity of tumour cells                         
(Liu et al., 1999). 
 
 
 
  
 
 
 
 
   
155 
 
A direct connection of EIF4e was observed with vimentin and GAPDH. In addition to its 
implication in prognosis of pancreatic cancer and breast cancer progression, EIF4e 
activated Sox2 in glial cells at the transitional level conferring them with pluripotency 
and self-renewal properties (Ge et al., 2010). EIF4e facilitates the synthesis of several 
powerful tumour angiogenic factors (FGF-2 and VEGF) by selectively enhancing their 
translation. Hypoxia increases EIF4e expression marking the transition of the vascular 
phase of cancer progression (Defatta et al., 1999). By promoting cellular proliferation 
through Akt activation, EIF4e helps serum-deprived cells to escape from the apoptotic 
stimuli (Culjkovic et al., 2008). EIF4e showed an identical expression in the hypoxic as 
well as serum-deprived cells, indicating that it serves as an oncogene promoting 
tumour progression under conditions of undifferentiation irrespective of the type of 
micro-environmental changes induced.  
HNRNPK is a protein that shows multiple interactions with other proteins related to 
different types of cancers. HNRNPK is directly involved in head and neck cancer, 
through ANXA2 it is related to cholangiocarcinoma, prostatic and cervical cancer. TPI1 
and HspA8 links HNRNPK to liver and hepatocellular carcinoma. This protein was found 
to be up-regulated by 5.1 fold in cells deprived of serum when compared to the 
hypoxic cells. In response to extra-cellular signals, HNRNPK directly regulates the rate 
of transcription and translation. An enhanced nuclear expression of HNRNPK was 
observed in fast proliferating cells with increased levels of tyrosine phosphorylation 
(Ostrowski and Bomsztyk, 2003). An elevated level of HNRNPK in serum free condition 
supplemented with growth factors may support the proliferation of cells; therefore, 
HNRNPK can be used as a differentiation marker. 
Cells of different origin derived from diverse molecular mechanisms give rise to 
different types of CSCs. A recent study performed on 17 glioblastoma multiforme 
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(GBM) CSC lines displayed two different groups of CSC lines: Type I “proneural” 
signature genes that resemble foetal NSC (fNSC; CD133+ and the formation of 
neurospheres) and Type II “mesenchymal” transcriptional profile similar to adult NSC 
(aNSC; CD133- and semi-adherent growth) (Lottaz et al., 2010). GBM originates from 
CSCs that arise with preserved features of NSC via the process of undifferentiation (Lee 
et al., 2006). Aligning the present proteomic studies to this research based on     24-
gene signature indicated that the state of hypoxia and serum deprivation could inhabit 
Type I CSCs. The proteins identified within the dataset included BMP2 which should be 
present in Type II CSCs, ELF4 and HSPs which should be expressed in Type II CSCs. In 
the entire study BMP2 protein expression was not detected, the proteomic 
investigation implicated an up-regulation of ELF4e and Hsp90β, supporting the 
hypothesis of Type I CSCs resembling fNSCs. Furthermore, Type II CSCs can be 
reprogrammed towards pluripotency by activation of Oct4 (Zheng et al., 2008). The 
absence of Oct4-A protein in the dataset provided by the proteomics analysis could be 
attributed to the post translational modification or degradation. An abundant 
expression of Oct4-A protein detected in the control, hypoxic and serum-deprived    
U87-MG cells by flow cytometric analysis and immunofluorescent studies indicate 
micro-environmental changes can induce stem like cells. However, there exists a 
different molecular mechanism which contributes to tumorigenesis via CD133-.  
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Conclusion 
In conclusion, the hypothesis that Oct4-A and BMP2 could be glioma stem cell markers 
did not prove to be correct. In this study observation of CD133 expression in hypoxic 
U87-MG cells through flow cytometric analysis indicated that CD133 could be used a 
marker for Type I stem cells or its progenitors which have acquired stem cell-like 
function due to an altered micro-environment. Undifferentiation conditions of serum 
deprivation did not display the expression of stem cell-related markers. However, the 
cells were found to be more chemosensitive as compared to the control and hypoxic 
cells. In addition, cell cycle analysis confirmed the chemotherapeutic potential of Taxol 
as compared to TMZ in inhibiting glioma cell proliferation. Furthermore, proteomic 
analysis provided an insight in the altered mechanism/s in the differentiated and 
undifferentiated cells as well as between the two different micro-environmental 
conditions used to attain the undifferentiated state (hypoxia and serum deprivation). 
The IPA analysis confirmed the participation of the majority of the proteins in altering 
the cell cycle phases that needs to be further investigated in order to understand the 
deregulated mechanism in NSCs and CSCs. Proteomic studies enlisted a few markers 
which could be selected to isolate CSCs from the bulk tumour mass using western blot 
technique. Proteins such as UDG, PGK1, HNRNPK and moesin can be used as markers 
to identify a group of differentiated cells in glioma. Vimentin, EIF4e, CSNK2A1 can be 
further investigated in downstream experiments to support proteomic analysis and to 
define their contribution in the initiation of brain tumours.  
The present study suggests that Laminin binding protein associated with Integrin α6β1 
and BMP2 could be explored in future research and as a potential biomarker for the 
isolation of glioma stem cells.   
 
 
  
 
 
 
 
   
158 
 
It could be hypothesised that both hypoxia and serum deprivation support the process 
of cellular undifferentiation. However, hypoxic conditions result in rapid onset of CSC 
related properties. Serum deprivation, on the other hand, introduces a gradual change 
in the stemness related features of the undifferentiated glioma cells. Both these    
micro-environmental changes result in the derivation of Type I CSCs. Further work 
needs to focus on identification of Type II CSCs based on their transcriptional and 
proteome profiles. Therapeutics, therefore need to identify both these sub types of 
CSCs and eliminate them in order to cure glioma. 
Future work (Molecular targets to study glioma stem cells) 
Cancer stem cells divide symmetrically resulting in identical daughter cells conferring 
them with self-renewal properties and asymmetric division results in a stem cell and a 
progenitor (Clarkes et al., 2006). However, recent data suggest that the description of 
asymmetric division within a cancer stem cell decides the cells fate by means of the 
segregation of the template DNA to the daughter cell (Pine et al., 2010). In order to 
draw a conclusion, two prospects need to be confirmed as to whether tumours 
originate from existing stem cells which have self-renewal capacity but acquire 
epigenetic and genetic alterations or the progenitor cells may act as cancer stem cells 
on attainment of their self-renewal ability (Clarkes et al., 2006). Both these 
probabilities could occur making it essential to confirm the role stem cells play in 
cancer. Moreover, resistance to drugs and therapeutic strategies have been associated 
with self-renewal properties of stem cells. A high expression of homeobox protein-A10 
(HOXA10; stem cell progenitor marker) gene together with the co-expression of 
growth arrest and DNA-damage-inducible protein, Gamma (GADD45G; cell cycle 
checkpoint gene) is responsible for resistance towards TMZ and chemotherapy in 
 
 
  
 
 
 
 
   
159 
 
general (Murat et al., 2008). An in depth study of the asymmetric division and 
discovery of such specific genes could help target CSCs and minimize drug resistance. 
The detection of recurrence cancer stem cells (rCSCs) could also be evidence towards 
tumour relapse. Cell fusion is the mechanism through which rCSCs are generated 
yielding highly proliferative hybrid cells. The origination of rCSCs occurs during first line 
therapy resulting into a cell progeny that is highly malignant and resistant to first line 
therapy that has been shown to have an increased resistance to apoptosis           
(Dittmar et al., 2009). It is believed that all tumour cells are fusogenic and their 
capacity to fuse remains unlimited, however, the grade of cell fusion differs amongst 
the tumour cell lines (Duelli and Lazebnik, 2003). Therefore, if fusion of a NSC with a 
tumour cell occurs there is a possibility that the resultant CSCs exhibit an enhanced 
proliferative potential with increased drug resistance. A study combining cancer cell 
division, drug-resistance, rCSCs and the stem cell niche could help identify true 
tumour-initiating cells. Furthermore, proteomic studies focusing on the cancer altered 
signalling pathways can provide a better understanding of glioma with regards to 
treatment. 
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